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Summary
Background—Understanding the patterns of HIV/AIDS epidemics is crucial to tracking and 
monitoring the progress of prevention and control efforts in countries. We provide a 
comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, 
and coverage of antiretroviral therapy (ART) for 1980–2017 and forecast these estimates to 2030 
for 195 countries and territories.
Methods—We determined a modelling strategy for each country on the basis of the availability 
and quality of data. For countries and territories with data from population-based seroprevalence 
surveys or antenatal care clinics, we estimated prevalence and incidence using an open-source 
version of the Estimation and Projection Package—a natural history model originally developed 
by the UNAIDS Reference Group on Estimates, Modelling, and Projections. For countries with 
cause-specific vital registration data, we corrected data for garbage coding (ie, deaths coded to an 
intermediate, immediate, or poorly defined cause) and HIV misclassification. We developed a 
process of cohort incidence bias adjustment to use information on survival and deaths recorded in 
vital registration to back-calculate HIV incidence. For countries without any representative data on 
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HIV, we produced incidence estimates by pulling information from observed bias in the 
geographical region. We used a re-coded version of the Spectrum model (a cohort component 
model that uses rates of disease progression and HIV mortality on and off ART) to produce age-
sex-specific incidence, prevalence, and mortality, and treatment coverage results for all countries, 
and forecast these measures to 2030 using Spectrum with inputs that were extended on the basis of 
past trends in treatment scale-up and new infections.
Findings—Global HIV mortality peaked in 2006 with 1·95 million deaths (95% uncertainty 
interval 1·87–2·04) and has since decreased to 0·95 million deaths (0·91–1·01) in 2017. New cases 
of HIV globally peaked in 1999 (3·16 million, 2·79–3·67) and since then have gradually decreased 
to 1·94 million (1·63–2·29) in 2017. These trends, along with ART scale-up, have globally resulted 
in increased prevalence, with 36·8 million (34·8–39·2) people living with HIV in 2017. Prevalence 
of HIV was highest in southern sub-Saharan Africa in 2017, and countries in the region had ART 
coverage ranging from 65·7% in Lesotho to 85·7% in eSwatini. Our forecasts showed that 54 
countries will meet the UNAIDS target of 81% ART coverage by 2020 and 12 countries are on 
track to meet 90% ART coverage by 2030. Forecasted results estimate that few countries will meet 
the UNAIDS 2020 and 2030 mortality and incidence targets.
Interpretation—Despite progress in reducing HIV-related mortality over the past decade, slow 
decreases in incidence, combined with the current context of stagnated funding for related 
interventions, mean that many countries are not on track to reach the 2020 and 2030 global targets 
for reduction in incidence and mortality. With a growing population of people living with HIV, it 
will continue to be a major threat to public health for years to come. The pace of progress needs to 
be hastened by continuing to expand access to ART and increasing investments in proven HIV 
prevention initiatives that can be scaled up to have population-level impact.
Funding—Bill & Melinda Gates Foundation, National Institute of Mental Health of the US 
National Institutes of Health (NIH), and the National Institute on Aging of the NIH.
Introduction
Between 2000 and 2015, excitement around the Millennium Development Goals (MDGs) 
galvanised more than US$500 billion in spending on prevention, care, and treatment for 
HIV/AIDS globally.1 Despite the subsequent decrease in overall HIV-related mortality, more 
than 36 million people still live with HIV/AIDS, which continues to be the underlying cause 
of death for almost 1 million people every year, concentrated in sub-Saharan Africa.2,3 
Recognising the sustained threat, UNAIDS set targets for the years 2020 and 2030 with the 
aim of ending the epidemic by 2030.4,5 In this study, we estimate the current and future 
burden of HIV/AIDS and track progress towards meeting these targets.
Complementing the ambitious Sustainable Development Goal (SDG) to end the HIV/AIDS 
epidemic by 2030, UNAIDS’ 90–90–90 targets (90% of people living with HIV diagnosed, 
of whom 90% are on treatment, of whom 90% are virally suppressed) have been set for 
2020, and 95–95–95 targets (95% of people living with HIV diagnosed, of whom 95% are 
on treatment, of whom 95% are virally suppressed) for 2030.5 In accordance with this fast-
track initiative to achieve the SDG goal, UNAIDS has since set targets for reducing the 
number of HIV incident cases and deaths between 2010 and 2020 by 75% and between 2010 
Page 2
Lancet HIV. Author manuscript; available in PMC 2019 December 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and 2030 by 90% for each country.4 Although these latest targets have helped to renew focus 
on the epidemic, measuring patterns in HIV/AIDS incidence, prevalence, and mortality is 
challenging, in part because of poor vital registration data and incomplete disease 
notification systems in high-burden areas, and complex disease modelling strategies and 
methodological limitations.6 Still, comprehensive global estimates are needed to track 
progress and understand future burden.
In this Article, we present results from the Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) 2017. We address several methodological and data-related challenges 
associated with estimating HIV burden to provide a comprehensive and robust assessment of 
trends in HIV incidence, prevalence, and mortality across 195 countries and territories from 
1980 to 2017. Building on previous iterations, we extensively updated population estimates 
and incorporated new prevalence data from national surveys and antenatal care clinics. 
Additionally, we generated country-level forecasts towards achieving targets associated with 
antiretroviral therapy (ART) coverage, HIV incidence, and HIV-related mortality. These 
forecasts enable us to report country-specific progress towards achieving the following 
targets: a reduction in the number of HIV incident cases of 75% between 2010 and 2020 and 
90% between 2010 and 2030; a reduction in the number of HIV deaths of 75% between 
2010 and 2020 and 90% between 2010 and 2030; 81% (90% started, 90% retained) ART 
coverage by 2020 and 90% (95% started, 95% retained) coverage by 2030.4,5
Methods
Study design and modelling strategy
GBD is a systematic, scientific effort to quantify the comparative magnitude of health loss 
due to diseases and injuries by age, sex, and geography over time. GBD 2017 includes 195 
countries and territories, 16 of which (Brazil, China, Ethiopia, India, Indonesia, Iran, Japan, 
Kenya, Mexico, New Zealand, Norway, Russia, South Africa, Sweden, the UK, and the 
USA) were analysed at the subnational level. The conceptual and analytical framework for 
GBD, hierarchy of causes, and detailed methods have been published elsewhere.2,3,7 The 
GBD protocol is also available online. Herein we describe the specific methods used for 
analysing the burden of HIV for GBD 2017.
Input data for modelling HIV morbidity and mortality include vital registration data, 
household seroprevalence surveys, data from antenatal care clinics, demographic estimates 
(population, fertility, migration, and HIV-free survival rates from GBD 2017), intervention 
coverage data reported to UNAIDS including ART, prevention of mother-to-child 
transmission, HIV mortality on and off ART, and rates of disease progression from a 
systematic review (appendix 1 pp 2–4).
The GBD framework for HIV/AIDS aims to produce internally consistent estimates for HIV 
incidence, prevalence, and mortality and relies on two established estimation models. We 
used the Estimation and Projection Package (EPP), an HIV epidemic model originally 
developed by the UNAIDS Reference Group on Estimates, Modelling, and Projections.8 
EPP uses Bayesian methods to infer force of infection from trends in HIV prevalence data. 
EPP generates incidence and prevalence estimates for individuals aged 15–49 years for both 
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sexes combined. We also used a modified version of Spectrum, a compartmental model used 
by UNAIDS that ages a population over time while applying HIV incidence, progression, 
and mortality to produce age-sex-specific HIV incidence, prevalence, and mortality.8
Multiple methodological improvements to both EPP and Spectrum were made for GBD 
estimation, including developing a model of ART coverage distribution as a function of 
income, age, sex, and disease progression that we used in Spectrum. Full details of 
modifications to EPP and Spectrum are in appendix 1 (pp 7–13).
To ensure appropriate modelling techniques, we grouped countries on the basis of 
availability and quality of data. Group 1 includes countries with HIV prevalence data from 
antenatal care clinics or representative population-based seroprevalence surveys. Group 1A 
includes countries with a peak of at least 0·5% prevalence, and group 1B includes countries 
with a peak prevalence of at least 0·25% plus vital registration completeness less than 65%. 
Group 2 includes all other countries, which are further classified as groups 2A, 2B, and 2C 
on the basis of availability of vital registration data. Group 2A locations have high-quality 
data, group 2B locations have at least some data, and group 2C locations have no data on 
HIV-specific mortality.2 The modelling framework by country grouping is shown in 
appendix 1 (pp 5, 6).
This study was approved by the University of Washington Institutional Review Board 
(application 46665).
Incidence and prevalence estimation
For group 1 countries, we used EPP to estimate incidence and prevalence for individuals 
aged 15–49 years, for both sexes combined, using population-based surveys and antenatal 
care clinic data. To account for bias created by the differences in HIV prevalence between 
pregnant women who attended an antenatal care clinic and the general population, we 
extracted data from available Demographic and Health Surveys on HIV prevalence among 
pregnant women who gave birth in the past year and who attended an antenatal care clinic. 
For antenatal care bias adjustment, we input this data into a regression model with regional 
random effects to generate country-specific prior distributions where surveys were available 
and regional prior distributions for locations without a survey. We then used the incidence 
and prevalence results from EPP as inputs in Spectrum to further disaggregate to age-sex-
specific HIV incidence and prevalence. We used the sex ratio of prevalence from population-
based surveys to inform the sex-splitting assumptions for adults in Spectrum, and applied 
default age-splitting assumptions from Spectrum.8 We calculated vertical transmission as a 
function of prevention of mother-to-child transmission inputs and age-specific fertility rates 
adjusted to account for differential fertility among women who were HIV positive.
For the Global Burden of Diseases, Injuries, and Risk Factors Study protocol see 
http://www.healthdata.org/gbd/about/protocol
See Online for appendix 1
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For group 2 countries, we developed a process called cohort incidence bias adjustment to 
estimate incidence and prevalence using mortality data. We ran a first stage of Spectrum to 
generate initial incidence, prevalence, and mortality curves, along with incidence cohort 
survival. We then calculated the bias between Spectrum mortality estimates and smoothed 
vital registration data for each year, which we used along with Spectrum cohort survival 
estimates to adjust incidence (appendix 1 pp 11–13). To account for sensitivity in our 
estimates to input incidence, we ran the first stage of Spectrum using various input incidence 
curves and selected the option with the smallest resulting bias in mortality estimates. We ran 
a second stage of Spectrum using adjusted incidence to produce age-sex-specific incidence 
and prevalence estimates. In countries with high-quality case notification data, we scaled 
incidence results to align with case reports after accounting for an assumed average of 5 
years’ lag between infection and diagnosis.9
Mortality estimation
We undertook a meta-analysis of cohort studies to derive on-ART and off-ART mortality as 
inputs into Spectrum and EPP. We estimated age-sex-specific, CD4-specific, region-specific, 
and duration-specific on-ART mortality using cohort data after correcting for loss to follow-
up (appendix 1 pp 4–7). We jointly estimated off-ART mortality and CD4 progression via an 
optimisation process that found a best fit to survival curves from cohort studies.
For group 1 countries, we generated age-sex-specific HIV mortality estimates in Spectrum 
using the incidence and prevalence estimated in EPP. For group 2 countries, we adjusted 
vital registration data for incompleteness and garbage coding (ie, deaths coded to an 
intermediate, immediate, or poorly defined cause).2 We further corrected the data for HIV 
misclassification by identifying causes of death that deviated from expected age patterns of 
mortality in years with known HIV epidemics, and excess deaths were attributed to HIV. We 
used spatiotemporal Gaussian process regression to smooth and complete the time series of 
adjusted vital registration data (appendix 1 p 11). For groups 2A and 2B, we used the 
smoothed vital registration data to inform Spectrum-estimated mortality through the cohort 
incidence bias adjustment process. In group 2C countries, we leveraged spatial information 
by sampling cohort incidence bias adjustment-generated incidence-adjustment scalars in the 
region, which were then input into Spectrum to create mortality estimates.
The GBD framework produced three distinct sources of HIV mortality estimates: HIV 
mortality results from Spectrum; estimated excess HIV mortality from the all-cause 
mortality process; and smoothed HIV-specific mortality from vital registration data.10 For 
group 1 countries, we used an ensemble approach to reconcile the differences between HIV 
mortality estimated by Spectrum and by the all-cause mortality process and generate final 
HIV mortality. In group 1 countries, EPP and Spectrum estimates were largely driven by 
HIV prevalence data and mortality estimates generated from cohort data, whereas the all-
cause mortality process was primarily based on sibling survival data. For individuals aged 15 
years and older, the ensemble model averaged HIV mortality estimates from the two 
processes with equal weights. For individuals younger than 15 years, we applied the fraction 
of deaths due to HIV in Spectrum to estimated all-cause mortality to generate HIV-specific 
mortality and mortality from all other causes (HIV-free mortality). In group 2A countries, 
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we estimated mortality only from vital registration data, and for group 2B and 2C countries 
we only used Spectrum results.
Forecasting to 2030
We forecasted HIV incidence, prevalence, mortality, and treatment coverage through to 2030 
in Spectrum using input parameters extended to 2030. We forecasted the adult ART 
coverage input on the basis of forecasted ART price, HIV spending on care and treatment, 
and lag-distributed income (ie, gross domestic product per capita that has been smoothed 
over the preceding 10 years). We modelled country-year-specific annual ART price per 
patient using Gaussian process regression with data from the Global Price Reporting 
Mechanism.11 We calculated the annualised rate of change of per-capita expenditure on HIV 
care and treatment in each country since 2010. We then forecast expenditure on HIV care 
and treatment for each country using the 50th percentile annualised rate of change across 
countries.1 We calculated annual dose-equivalents of ART by dividing spending by ART 
price, and we used logistic regression to model the association between annual dose-
equivalents and ART coverage. We forecasted other treatment coverage inputs to Spectrum, 
such as child ART coverage and prevention of mother-to-child transmission, using the same 
approach based on the 50th percentile annualised rate of change observed across countries. 
Forecasting the incidence input had two steps. First, we calculated counterfactual incidence 
(ie, expected incidence in the absence of ART) using an assumption of 70% viral 
suppression among those on treatment,12 then we forecast counterfactual incidence using the 
50th percentile annualised rate of change observed across countries in the previous 5 years. 
Because the forecasted incidence was derived from the counter-factual incidence using 
forecasted ART coverage, the final forecasted incidence changed in response to both the 
underlying secular trend and improvements in ART coverage. We used forecasted 
demographic inputs that were estimated for each location,13 then we ran Spectrum for all 
locations. Full details on the methods for forecasting are in appendix 1 (pp 17–22). We used 
the mean values (rounded to the nearest integer) of the resultant HIV forecasts to determine 
whether countries were on track to meet the 2020 and 2030 UNAIDS targets.
Uncertainty analysis
We propagated uncertainty by generating 1000 draws of key inputs, including draw-level 
linkage of HIV-free mortality with the GBD all-cause mortality process. We ran EPP and 
Spectrum 1000 times per location to generate results for each draw. We present results with 
95% uncertainty intervals (UIs).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or the writing of the report. All authors had full access to the data in the study 
and had final responsibility for the decision to submit for publication
Results
Global deaths from HIV peaked in 2006 and have since decreased from 1·95 million (95% 
UI 1·87–2·04) deaths in 2006 to 0·95 million (0·91–1·01) in 2017 (figure 1). Global ART 
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coverage increased from 2·98 million (2·44–3·58) in 2006 to 21·8 million (20·7–22·9) in 
2017. The number of new HIV infection cases peaked in 1999 (3·16 million [2·79–3·67]) 
and has gradually decreased thereafter. Between 2007 and 2017, the global age-standardised 
annualised rate of change in HIV incidence decreased by 3·0% (1·5–4·5), with the number of 
new cases decreasing from 2·35 million (2·02–2·76) in 2007 to 1·94 million (1·63–2·29) in 
2017 (table, figure 1). The confluence of these trends produces a steady increase in the total 
number of people living with HIV. Prevalence has increased from 8·74 million (7·90–9·68) 
people living with HIV in 1990 to 36·8 million (34·8–39·2) in 2017, of whom 40·5% (37·8–
43·7) were not on ART.
In both 2007 and 2017, younger adults (aged 25–49 years) comprised a high percentage of 
all HIV deaths compared with all other age groups (figure 2). Our estimates highlight 
differences in HIV burden between males and females. Females aged 30–34 years had the 
highest percentage of HIV deaths of all female age groups, 16·4% (95% UI 15·7–16·9) in 
2007 and 14·9% (13·8–15·7) in 2017, whereas males aged 35–39 years had the highest 
percentage of HIV deaths of all male age groups, 15·9% (14·9–16·8) in 2007 and 14·8% 
(13·8–15·8) in 2017. New infections among women were mostly among younger adults, 
with 20·8% (19·2–22·4) of new infections occurring among females aged 20–24 years in 
2017, relatively unchanged from the incidence in 2007 (20·9%, 19·8–22·1). In 2017, males 
aged 25–29 years had the highest incidence of all male age groups, accounting for 18·6% 
(16·1–23·1) of new infections that year, which is a substantial change from 2007, when the 
highest incidence in males occurred among those younger than 1 year. Although HIV 
infections in children have decreased substantially with the scale-up interventions for 
prevention of mother-to-child transmission, in 2017, 139 555 (121 893–159 064) new 
infections were in children younger than 1 year, and 122 254 (112 228–132 591) HIV deaths 
were in children younger than 15 years. Most HIV deaths in people younger than 15 years 
are in children younger than 5 years, but this proportion has decreased from 82·1% (82·0–
82·1) in 2007 to 63·4% (60·8–65·8) in 2017, showing the increase in lifespan for children 
who are HIV positive.
Along with substantial variation in ART coverage (figure 3), sub-Saharan Africa had the 
highest prevalence of HIV in 2017 (figure 4). Males in three countries (Gabon, eSwatini, and 
Zimbabwe) and females in five countries (Gabon, Rwanda, Botswana, eSwatini, and 
Zimbabwe) with HIV prevalences of greater than one per 1000 population reached ART 
coverage of 81% or higher in 2017, reflecting early attainment of the second 90 of the 
UNAIDS 90–90–90 targets (figure 3). Countries across southern sub-Saharan Africa 
achieved higher proportions of treatment coverage than those in other sub-Saharan African 
regions, ranging from 66% in Lesotho to 86% in eSwatini. The estimated proportion of 
people living with HIV who were on treatment was higher among women than men in all 
but eight countries in sub-Saharan Africa (Angola, Benin, Cape Verde, Democratic Republic 
of the Congo, Djibouti, Eritrea, Madagascar, and São Tomé and Príncipe). Additional results 
detailing proportions of males and females on and off ART by GBD super-region are in 
appendix 2 (pp 25–31). Overall ART coverage has increased substantially over the past 
decade in some countries (figure 5). Between 2007 and 2017, 42 countries had annualised 
rates of change in ART coverage greater than 25%.
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In 2017, South Africa had a higher number of new infections than all other countries, with 
0·28 million (95% UI 0·21 to 0·35) new cases (table). The incidence for both sexes was 
highest in Lesotho in 2017, where the age-standardised rate of new cases was 6·2 (4·5 to 8·2) 
per 1000 population (figure 4). From 2007 to 2017, the annualised rate of change in 
incidence in Lesotho was −7·1% (95% UI −10·7 to −4·4), which is a drastic change from the 
positive annualised rate of change in incidence from 1990 to 2007 (2·8%, 1·1 to 4·5; table). 
Substantial progress has been made by most countries in sub-Saharan Africa, and Comoros 
was the only country that had an increase in incidence from 2007 to 2017, with an 
annualised rate of change of 12·8% (0·7 to 23·5). By contrast, many countries in eastern 
Europe and central Asia saw a sharp increase in the number of new infections in the past 
decade, with the highest annualised rate of change seen in Russia at 13·2% (10·3 to 15·5). 
Most countries in western Europe and North America also showed stagnant or increasing 
annualised rates of change in incidence (table).
Between 2007 and 2017, 122 of 195 countries had a decrease in the rate of change in age-
standardised HIV mortality. Notably, the countries that achieved the most rapidly decreasing 
annual rates of change were Ethiopia (−19·7%, 95% UI −20·9 to −18·4), Burundi (−19·9%, 
−22·1 to −16·8), and Zimbabwe (−20·8%, −22·9 to −17·4; table). Lesotho had the highest 
age-standardised mortality in 2017, with mortality for both sexes combined being 3·4 (95% 
UI 3·0 to 4·0) per 1000 population (figure 4). The annualised rate of change in mortality 
between 2007 and 2017 in Lesotho was −10·9% (−11·9 to −9·2), and prevalence in Lesotho 
increased from 153·2 (142·7 to 164·7) per 1000 population in 2007 to 177·8 (168·9 to 187·8) 
per 1000 population in 2017 (data available from GBD datahub).
See Online for appendix 2
For the Global Health Data Exchange for 2017 see http://ghdx.healthdata.org/gbd-2017
In our forecasting, we found that progress towards meeting the ART coverage target is more 
optimistic than progress towards the incidence or mortality targets. Global ART coverage 
was forecast to be 64·8% (95% UI 61·1–67·0) in 2020 and 71·9% (68·2–75·0) in 2030 
(appendix 2 pp 3–12). A substantial number of countries are predicted to meet ART 
coverage targets (figure 6), with 54 countries expected to meet the 2020 target of 81% ART 
coverage (90% started, 90% retained) and 12 expected to meet the 2030 target of 90% ART 
coverage (95% started, 95% retained). Of the 54 countries forecast to meet the 2020 ART 
coverage target, 25 are in the high-income super-region; 11 are in central Europe, eastern 
Europe, and central Asia; ten are in sub-Saharan Africa; six are in Latin America and the 
Caribbean; and two are in other regions (Mauritius and Kuwait; figure 6; appendix 2 pp 3–
12). Looking ahead, 38 countries had a forecast coverage of at least 85% but less than the 
90% target in 2030.
Compared with ART coverage, fewer countries are expected to achieve the UNAIDS 2020 
or 2030 targets associated with mortality (figure 7; appendix 2 pp 13–18). Six countries 
(Burundi, Ethiopia, Gabon, eSwatini, Zambia, and Zimbabwe) were forecasted to achieve 
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the 2020 target for mortality percentage reduction and two (Ethiopia and eSwatini) were 
forecasted to achieve the 2030 target. Although still short of the target, an additional eight 
countries (Botswana, Democratic Republic of the Congo, India, Cambodia, Myanmar, Togo, 
Tanzania, and South Africa) were forecasted to have a reduction in mortality of at least 65% 
between 2010 and 2020, and six (Burundi, Botswana, Gabon, Cambodia, South Africa, 
Zambia) were forecasted to have a reduction of at least 80% between 2010 and 2030. 
Forecasted trends in incidence show the least progress, with no countries meeting the 
UNAIDS 2030 target (figure 7; appendix 2 pp 19–24).
Discussion
Globally, great progress has been made in reducing HIV-related incidence and mortality 
since their peaks earlier in the epidemic, consistent with the positive trend in ART coverage. 
Despite the scale-up of ART over time, in 2017, 40·5% (95% UI 37·8–43·7) of the 36·82 
million (34·79–39·20) people estimated to be living with HIV globally were still not on 
treatment. In the same year, 1·94 million (1·63–2·29) people were newly infected with HIV 
and 0·95 million (0·91–1·01) people died from HIV-related causes. Trends in new infections 
and mortality are our primary indicators of progress, and over the past decade HIV incidence 
has been decreasing more slowly than mortality. Thus, decreases will need to be accelerated 
to achieve global targets. Although 54 countries are on track to meet the 2020 target of 81% 
ART coverage (90% started, 90% retained), only 12 countries are expected to meet the 2030 
target of 90% ART coverage (95% started, 95% retained). Our forecasts show that fewer 
than ten countries will meet the mortality or incidence targets in 2020 and 2030.
Annualised rates of change in age-standardised HIV incidence and mortality between 2007 
and 2017 varied considerably across countries. The substantial decreases in many sub-
Saharan African countries underscore the enormous effort by governments and multilateral 
organisations to improve HIV prevention and provide effective treatment in these countries. 
For example, in Zimbabwe, high levels of personal exposure to AIDS deaths and prevention 
campaigns coupled with a relatively well educated population appear to have shifted social 
norms and catalysed partner reduction, which are thought to have contributed to steep 
decreases in HIV prevalence.14 eSwatini saw success after implementation of a multisectoral 
response with investments that prioritised ART scale-up, voluntary medical male 
circumcision, and prevention interventions aimed at adolescent women, mother-to-child 
transmission of HIV, and tuberculosis–HIV co-infection.15 Scale-up of a combination 
strategy of ART and medical male circumcision, funded by the President’s Emergency Plan 
for AIDS Relief (PEPFAR), was found to have population-level impact in Uganda in 
reducing incidence.16 Decreases in HIV burden in Botswana have been attributed to nearly 
complete coverage of interventions for prevention of mother-to-child transmission and 
expansion of ART, which might also have reduced stigma.17
Conversely, between 2007 and 2017 many countries in eastern Europe and central Asia saw 
increasing rates of new HIV infections and persistently high mortality; Russia reached the 
highest annual increase in incidence at 13·2% (95% UI 10·3–15·5). The growing epidemic 
seen in much of eastern Europe and central Asia stems from multiple factors, including 
limited access to ART, inadequate access to harm-reduction services (eg, needle and syringe 
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programmes, and opioid substitution therapy), and high levels of stigma.18 Opioid 
substitution treatment has been shown to lead to substantial reductions in risk of HIV 
infection among people who inject drugs; however, opioid substitution therapy remains 
unavailable in Russia.19 The particularly steep increases in new infections in Russia could 
also be linked to poor access to care for high-risk populations and elimination of Global 
Fund support.20
Our results showed stagnant or increasing annualised rates of change in incidence in many 
countries in western Europe and North America. In these countries, the HIV epidemic is 
largely driven by men who have sex with men (MSM).21 Challenges in the scale-up of HIV 
prevention programmes for MSM have been reported, including limited access to HIV 
testing and care and financial barriers.22 For example, the US Centers for Disease Control 
and Prevention estimated that MSM accounted for 66% of all HIV diagnoses in 2017 in the 
USA, and studies have shown high proportions of MSM are unaware of their status.23,24 
Increasing testing among high-risk populations is paramount to HIV prevention, because 
those who are aware of their status can decrease the risk of future transmission.24,25 
Additionally, increases in injection drug use in the USA have been linked with HIV 
outbreaks, and treatment efforts could be improved because fewer than 10% of those 
dependent on opioids are receiving substitution therapy.26
We found higher proportions of new infections among younger women (aged 20–24 years) 
than in men of the same age group in 2017. Higher risk of HIV infection among young 
women than in young men has been linked to several factors, including social factors such as 
poverty and low education, cultural factors such as transactional sex, laws that deter young 
women from accessing sexual and reproductive health services, and exposure to intimate 
partner violence.27,28 Ambitious interventions that address multiple causes of young 
women’s vulnerability to HIV infection in sub-Saharan African countries are underway.29
Few countries are on track to meet the global targets for incidence. Achieving reductions in 
incidence is complex because it requires increased coverage for both prevention and 
treatment interventions. A large body of literature has explored various intervention options.
30
 The HIV prevention cascade has been proposed as a novel framework to guide and 
monitor the design of interventions to maximise coverage at the population level. 
Krishnaratne and colleagues30 found that direct interventions, including overall pre-exposure 
prophylaxis medications and medical male circumcision, were efficacious for reducing 
incidence. Additionally, the consensus statement issued in 2016, and endorsed by over 760 
organisations to date, states that undetectable viral load is equivalent to non-transmittable 
infection based on strong scientific evidence that HIV cannot be transmitted sexually by 
those with an undetectable viral load.31 This evidence suggests that increasing access to 
early treatment and interventions to improve adherence can support further decreases in 
incidence. Still, few countries are forecast to achieve the 2030 ART coverage target of 95% 
covered and 95% retained.
Although treatment access and prevention mechanisms exist and can be widely 
implemented, inadequate ART coverage and adherence could perpetuate the AIDS epidemic. 
Achieving exceptionally high ART coverage involves reaching groups that are difficult to 
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target for testing and treatment. We estimate substantially lower ART coverage among men 
across most of sub-Saharan Africa than in other regions, which could stem from tendencies 
among men to delay presentation to testing and care.32 Additionally, in many parts of sub-
Saharan Africa and other high-burden locations, large rural catchment areas further 
compound barriers to HIV treatment services. Developments in the area of geospatial 
modelling point to emerging opportunities to improve access and delivery of health 
interventions at the population level.33
Despite the substantial progress made in reducing HIV-related mortality globally, only a 
small number of countries are on track to meet the 2020 and 2030 mortality targets. To 
accelerate the decrease in HIV-related mortality, prevention, early detection, and treatment 
of opportunistic infections such as tuberculosis should be a priority. Integration of services 
for HIV and tuberculosis, a leading cause of mortality among people living with HIV, is 
crucial as a strategy to increase linkage to HIV care and tackle the double burden of HIV 
and tuberculosis.34
These findings should be viewed in the context of global financing for HIV/AIDS. The 
excitement around the MDGs and the goal to achieve universal access to treatment for HIV/
AIDS by 2010 catalysed substantial resources to tackle the epidemic. Our estimates are 
consistent with the positive results of such global investment. However, the current and 
future costs of HIV/AIDS interventions and the ability of stakeholders to meet global needs 
will affect the epidemic going forward.
Moreover, the costs of the epidemic are likely to change. In 2015, US$27·3 billion was spent 
globally on HIV/AIDS care and treatment, amounting to more than half (55·8%) of the 
$48·9 billion spent on HIV/AIDS annually.1 HIV care and treatment includes services in 
both inpatient and outpatient settings, financed primarily through government spending and 
externally sourced development assistance for health. With access to ART, extended 
lifespans could continue to increase the total number of people living with HIV and thus 
further increase demand for treatment. Although the development of new therapies might 
reduce the per-person cost to treat those living with HIV, drug resistance that is emerging 
alongside increased access to ART could compound progress by increasing the cost of 
treatment and necessitating additional resistance testing on a wider scale.35 Therefore, 
decision makers need to anticipate the costs of providing treatment and look to prioritise 
prevention to reduce future costs. The GBD Health Financing Collaborator Network 
assessed that the annualised rate of support per prevalent case had increased between 2000 
and 2010 but had subsequently decreased between 2010 and 2015.1 The gap that exists 
between available resources and what is needed to achieve global targets will require 
renewed mobilisation of resources, otherwise the decrease in development assistance for 
HIV/AIDS could hinder progress.
Although UNAIDS and GBD use similar approaches to modelling the burden of HIV, key 
differences exist in data and methods. At the global level, UNAIDS and GBD estimate 
similar mortality and prevalence; however, GBD estimates slightly higher incidence.36 
Incidence in recent years is difficult to estimate because of the paucity of data and need to 
infer incidence from prevalence data. Therefore, recent estimates are highly sensitive to 
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model specification. For group 2 countries, one primary data difference is that the GBD uses 
vital registration data as an input for models, using a uniform approach to cleaning data, 
accounting for garbage coding, and generating full time-series estimates of HIV mortality 
with uncertainty. While some countries might use vital registration data when producing 
official UNAIDS estimates, not all countries with data of sufficient quality include it as an 
input in their model, and heterogeneous data processing restricts comparability. Another 
methodological difference is that for allocation of ART to different ages, sexes, and disease 
severity levels, UNAIDS uses an average of the expected number of deaths and the number 
of people in each untreated CD4 count group to allocate ART, whereas GBD uses a model to 
determine the association between a country’s economic status and the allocation of 
treatment.
Globally, more than one in eight new HIV infections occur in South Africa, making global 
trends highly sensitive to differences in estimates for South Africa. UNAIDS estimates for 
South Africa are based on a bespoke epidemic model (Thembisa), which differs in its 
complexity and input data from the model used for the rest of sub-Saharan Africa.37 The 
Thembisa-based model estimates a lower peak of incidence (13·81 in 1999 in UNAIDS 
estimates vs 14·58 per 1000 in 2000 in GBD estimates), a steeper decrease in incidence 
between 2007 and 2012 (−28% in UNAIDS estimates vs −12% in GBD estimates), and a 
slower decrease in incidence between 2012 and 2017 than GBD does (−28% in UNAIDS 
estimates vs −34% in GBD estimates).36 Similarly, the same model estimates a faster 
decrease in the number of deaths between 2007 and 2012 (−50% in UNAIDS estimates vs 
−23% in GBD estimates), and a slower decrease in deaths between 2012 and 2017 (−29% in 
UNAIDS estimates vs −45% in GBD estimates).36
This study has several limitations. First, our incidence and prevalence estimates in countries 
with vital registration data are driven by back-estimation from mortality data using 
assumptions of disease progression and survival. This estimation process relies on 
knowledge of the distribution of deaths occurring in each year for each incidence cohort. 
The back-calculation is inherently uncertain in more recent years when a smaller proportion 
of each incidence cohort has died. Second, for countries without prevalence data for which 
we do not run EPP, we must run a first stage of Spectrum using input incidence estimates. 
Our final prevalence results have shown considerable sensitivity to this initial incidence. We 
have attempted to mitigate this sensitivity by testing several options for input incidence and 
selecting the one that produces the closest fit to mortality data for each location, yet we 
expect that sensitivity to input incidence might still result in overestimated HIV burden in 
some locations, such as Portugal. Third, in group 1 countries, we have little cause-specific 
mortality data and rely on prevalence data and HIV mortality data derived from cohort 
studies to model HIV deaths. This limitation is reflected by wider UIs for results in these 
locations. For on-ART mortality, we pooled data from across countries in sub-Saharan 
Africa, and although this process results in reliable regional estimates, it means that our 
model does not incorporate variation in treatment quality or health system access by country. 
Fourth, importantly, our estimates are subject to the data available at the time of analysis. 
New data sources will be incorporated in future iterations of analyses as they become 
available. Finally, although our forecasted incidence accounts for direct effects of ART in 
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reducing a first generation of transmission, they do not incorporate compounding secondary 
transmission dynamic effects.
Despite these limitations, we made several improvements in our methods compared with 
previous GBD analyses. In GBD 2017, we modelled ART coverage distribution in Spectrum 
as a function of national wealth and disease progression. Whereas previous iterations of 
GBD used a version of Spectrum that disproportionately allocated ART to those with lower 
CD4 counts, the new model reflects earlier access to treatment regardless of disease 
progression for people living with HIV in higher-income countries. We also improved our 
estimation of paediatric HIV burden by modelling natural disease progression and informing 
child ART initiation and mortality using cohort data. Additionally, previous iterations 
assumed the same sex distribution of HIV burden across countries with generalised 
epidemics, but we now use a model fit to the sex ratio of prevalence from representative 
surveys to better reflect geographical variation.
Despite the considerable progress made in reducing HIV-related mortality and increasing the 
coverage of ART, HIV continues to be an enormous health burden globally. Up-to-date 
information on the trends of the HIV epidemic from the GBD 2017 study provides an 
opportunity to track the success of HIV control efforts and understand where interventions 
are having an impact. Our results show that decreases in mortality have out-paced decreases 
in incidence, therefore much needs to be done to prevent new cases of HIV. Additionally, at 
their current rates, many countries are not on track to reach the 2020 and 2030 UNAIDS and 
SDG targets. To truly end the HIV epidemic, the pace of progress needs to increase. Strides 
in this direction can be made by continuing to expand universal access to ART and 
increasing investments in proven HIV prevention initiatives that can scale to have 
population-level effects.
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Research in context
Evidence before this study
The levels and trends of the global HIV/AIDS epidemic have been estimated by two 
groups: the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and 
UNAIDS.
We searched PubMed with the search terms hiv[MeSH] AND (“mortality” OR 
“incidence” OR “prevalence”) AND “global” AND (trend*), with no language 
restrictions, for articles published since database inception until Nov 7, 2018. We did not 
identify any additional studies that provided comparable evaluations of the global trends 
in the HIV/AIDS epidemic across countries. The last GBD on HIV was in 2015; 
however, it did not include assessment of achieving UNAIDS targets using forecasts of 
past trends and associations in the data.
Added value of this study
For GBD 2017, the main inputs for our estimation of global HIV trends were 
systematically updated. These updates include a comprehensive update of population 
estimates that are internally consistent with fertility and mortality estimates for GBD 
2017, and incorporate new prevalence data from national surveys and antenatal care 
clinics. Additionally, we made improvements in our estimation of paediatric HIV via 
modelling of natural disease progression and incorporating cohort data on child 
antiretroviral therapy (ART) initiation and mortality. We also better reflected 
geographical differences in the sex-specific distribution of HIV burden on the basis of a 
model fit to the sex ratio of prevalence observed in countries with representative surveys. 
Finally, we used forecasting methods to generate country-level estimates towards 
achieving global targets related to ART coverage, HIV incidence, and HIV-related 
mortality by 2020 and 2030.
Implications of all the available evidence
By improving and extending existing HIV/AIDS burden estimates, this study provides 
valuable insight into progress towards Sustainable Development Goal 3’s target to end 
the AIDS epidemic by 2030 and the fast-track strategy to do so. Relative to incidence and 
mortality, more countries are on track to meet ART coverage targets of 81% (90% started, 
90% retained) by 2020 and 90% (95% started, 95% retained) by 2030. The relative 
progress necessary to achieve the 2020 and 2030 targets for reduction in incidence and 
mortality is not on pace in most countries. Renewed attention and investment in HIV 
prevention initiatives could help to restore global propensity to meet these targets. This 
study’s assessment of current trends and progress towards ambitious global targets 
provides evidence for decision makers to respond to current needs and plan for a future 
free of HIV/AIDS.
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Figure 1: Global HIV incidence, prevalence, mortality, and people on ART, by sex, for all ages, 
1980–2017
Shaded areas are 95% uncertainty intervals. ART=antiretroviral therapy.
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Figure 2: 
Percentage of deaths and new cases of HIV occurring in each age group, by sex, 2007 and 
2017
Page 31
Lancet HIV. Author manuscript; available in PMC 2019 December 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3: Proportion of people living with HIV who are on and off ART in sub-Saharan Africa, 
2017, by country and sex
Countries are subdivided by total HIV prevalences of 27 to 213 per 1000 population (A), 9 
to <27 per 1000 population (B), and 0 to <9 per 1000 population (C). Proportions given in 
bar charts are for those on ART. ART=antiretroviral therapy.
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Figure 4: Age-standardised HIV incidence (A), prevalence (B), and mortality (C) for both sexes, 
2017
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=islands. 
FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. 
TLS=Timor-Leste.
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Figure 5: All-age annualised rate of change of ART coverage between 2007 and 2017, both sexes
ART=antiretroviral therapy. ATG=Antigua and Barbuda. VCT=Saint Vincent and the 
Grenadines. Isl=islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. 
TTO=Trinidad and Tobago. TLS=Timor-Leste.
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Figure 6: Forecast of percentage ART coverage in 2020 and 2030, by country
Each datapoint is a country. ART=antiretroviral therapy.
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Figure 7: Forecast percentage decrease in HIV mortality (A) and incidence (B) from 2010 to 2020 
and 2030, by country
Each datapoint is a country. The plots are truncated at 100% increase, so in (A) 47 countries 
have been excluded and in (B) 35 countries have been excluded.
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Table:
Number of HIV incident cases and deaths in 2017 by sex and annualised rate of change of HIV incident cases 
and deaths for 1990–2007 and 2007–17, for 21 GBD regions and 195 countries and territories
New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
Global 966 000 
(786 
000 to 
1180 
000)
976 000 
(835 
000 to 
1120 
000)
1940 
000 
(1630 
000 to 
2290 
000)
446 000 
(417 000 to 
479 000)
508 000 
(483 
000 to 
540 
000)
954 
000 
(907 
000 to 
1010 
000)
−0·4% 
(−1·2 to 
0·3)
−3·0% 
(−4·5 to 
−1·5)
8·5% (7·8 
to 9·1)
−8·3% 
(−8·7 to 
−7·9)
Low SDI 259 000 
(176 
000 to 
378 
000)
177 000 
(124 
000 to 
257 
000)
436 000 
(303 
000 to 
627 
000)
132 000 
(120 000 to 
147 000)
131 000 
(121 
000 to 
143 
000)
262 
000 
(244 
000 to 
286 
000)
−5·2% 
(−6·2 to 
−4·2)
−5·9% 
(−9·4 to 
−2·0)
4·6% (3·6 to 
5·7)
−12·4% 
(−13·0 
to 
−11·8)
Low-middle 
SDI
359 000 
(271 
000 to 
459 
000)
278 000 
(212 
000 to 
356 
000)
636 000 
(487 
000 to 
808 
000)
192 000 
(170 000 to 
217 000)
184 000 
(163 
000 to 
207 
000)
375 
000 
(338 
000 to 
416 
000)
−1·6% 
(−2·8 to 
−0·5)
−4·1% 
(−6·1 to 
−2 0)
11·3% (10·0 
to 12 4)
−8·5% 
(−9·1 to 
−7·8)
Middle SDI 240 000 
(196 
000 to 
287 
000)
280 000 
(245 
000 to 
317 
000)
521 000 
(450 
000 to 
591 
000)
105 000 (94 
500 to 119 
000)
153000 
(143000 
to 
165000)
258 
000 
(241 
000 to 
278 
000)
6·0% (4·0 
to 8·2)
−3·7% 
(−5·3to 
−2·1)
18·6% (17·9 
to 19·3)
−7·8% 
(−8·5 to 
−7·2)
High-middle 
SDI
80800 
(69100 
to 99 
400)
167000 
(139000 
to 
198000)
247000 
(210000 
to 
297000)
14200 
(13700 to 
14800)
31500 
(30800 
to 
32700)
45700 
(44600 
to 
47500)
3·7% (3·2 
to 4·3)
7·5% 
(5·6to9·2)
4·6% (4·5 to 
4·8)
0·7% 
(0·5 to 
1·1)
High SDI 26700 
(15300 
to 
39200)
73100 
(42900 
to 
107000)
99800 
(58300 
to 
146000)
3170 (3140 
to 3200)
8700 
(8610 to 
8800)
11900 
(11800 
to 
12000)
−2·5% 
(−3
·
9 to 
−1·0)
1·9% 
(−0·8 to 
3·2)
−5·7% (−5·8 
to −5·7)
−5·3% 
(−5·4 to 
−5·2)
Central 
Europe, 
eastern 
Europe, and 
central Asia
59300 
(49400 
to 
74000)
121000 
(94800 
to 
149000)
180000 
(146000 
to 
222000)
8260 (8170 
to 8350)
18700 
(18400 
to 
18900)
26900 
(26700 
to 
27100)
8·1% (7·0 
to 9·2)
11·7% 
(9·1 to 
13·5)
7·7% (7·6 
to 7·8)
1·8% 
(1·7 to 
2·0)
Central Asia 3280 
(2200 to 
4480)
4030 
(2950 to 
5110)
7300 
(5200 to 
9550)
398 (377 to 
419)
902 
(869 to 
935)
1300 
(1260 
to 
1340)
4·2% (2·2 
to 6·3)
7·2% (3·7 
to 9·8)
6·8% 
(6·6to7·2)
−0·6% 
(−1·0 to 
−0·2)
 Armenia 65·3 
(46·1 to 
91·6)
99·6 
(67·6 to 
154)
165 
(120 to 
241)
5·7 (5·2 to 
6·2)
18·0 
(17·1 to 
19·0)
23·7 
(22·7 
to 
24·8)
21·1% 
(11·6 to 
59·7)
7·5% (4·1 
to 12 7)
11·7% (11·3 
to 12·0)
10·7% 
(10·0 to 
11·3)
 Azerbaijan 91·2 
(60·5 to 
127)
260 
(157 to 
416)
351 
(222 to 
535)
7·8 (5·5 to 
9·8)
23·7 
(17·9 to 
2 8·3)
31·5 
(23·8 
to 
37·8)
2·4% (−5·8 
to 5·8)
9·5% (5·2 
to 12·9)
6·4% (3·5 to 
14·8)
−8·0% 
(−11·2 
to −5·0)
 Georgia 108 
(74·0 to 
160)
283 
(181 to 
491)
391 
(256 to 
641)
8·5 (7·9 to 
9·1)
25·9 
(24·5 to 
27·4)
34·4 
(32·9 
to 
35·9)
18·4% 
(12·8 to 
25·9)
2·2% 
(−0·0 to 4 
4)
8·7% (8·3 to 
9·1)
17·6% 
(17·0 to 
18·3)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
Kazakhstan
988 
(640 to 
1440)
1510 
(1000 to 
1880)
2500 
(1670 to 
3220)
72·6 (67·2 
to 78·2)
186 
(175 to 
198)
258 
(246 to 
271)
2·5% (0·9 
to 4·2)
12·1% 
(8·0 to 
14·2)
7·8% (7·5 to 
8·2)
−2·1% 
(−2·7 to 
−1·6)
 Kyrgyzstan 457 
(291 to 
719)
447 
(275 to 
707)
904 
(575 to 
1390)
53·9 (50·2 
to 57·6)
133 
(126 to 
140)
187 
(179 to 
194)
8·9% (7·3 
to 11·1)
6·2% (1·1 
to 10·7)
9·2% 
(8·8to9·5)
1·6% 
(1·0 to 
2·2)
 Mongolia 11·5 (2 
3 to 
29·5)
48·7 
(11·3 to 
105)
60·2 
(14·9 to 
132)
3·8 (0·3 to 
11·1)
16·1 
(1·6 to 
32·9)
19·9 
(2·1 to 
44·0)
25·1% 
(47·5 to 
58·1)
6·7% (0·2 
to 11·6)
35·4% (43·1 
to 49·1)
8·2% 
(−11·0 
to 13 4)
 Tajikistan 419 
(184 to 
633)
156 
(95·4 to 
224)
575 
(280 to 
819)
29·8 (21·3 
to 44·2)
14·7 
(12·2 to 
18·1)
44·5 
(34·3 
to 
60·5)
2·4% (−0·6 
to 4·5)
9·1% (2·4 
to 13·3)
14·1% (11·0 
to 18·8)
−13·5% 
(−16·5 
to −9·5)
Turkmenistan
44·6 
(32·4 to 
69·4)
116 
(88·5 to 
169)
160 
(122 to 
236)
26·4 (24·4 
to 28·8)
73·0 
(68·7 to 
77·6)
99·5 
(94·6 
to 105)
−6·4% 
(−10·1 to 
−1·7)
2·2% (0·3 
to 4·4)
2·5% (2·2 to 
2·9)
−2·5% 
(−3·1 to 
−1·8)
 Uzbekistan 1090 
(330 to 
1910)
1100 
(305 to 
2000)
2200 
(650 to 
3780)
189 (174 to 
204)
413 
(390 to 
436)
601 
(575 to 
628)
5·0% (0·8 
to 11·4)
5·1% 
(−7·3 to 
11·6)
5·1% (4·8 to 
5·4)
1·0% 
(0·3 to 
1·5)
Central 
Europe
529 
(401 to 
669)
1600 
(1260 to 
2120)
2130 
(1670 to 
2770)
126 (118 to 
144)
395 
(356 to 
462)
521 
(476 to 
604)
6·3% (4·4 
to 8·0)
−0·1% 
(−2·1 to 
1·4)
−0·0% (−0 
·4 to 0·8)
−0·9% 
(−1·7 to 
−0·1)
 Albania 0·9 (0·7 
to 1·4)
2·1 (1·5 
to 3·0)
3·0 (2·2 
to 4·3)
0·4 (0·4 to 
0·5)
0·9 (0·8 
to 1·0)
1·3 
(1·1 to 
1·5)
0·4% (−0 4 
to 1·3)
2·0% (0·2 
to 3·7)
2·9% (2·0 to 
4·2)
−3·6% 
(−4·8 to 
−2·4)
 Bosnia and 
Herzegovina
1·2 (0·8 
to 1·6)
2·2 (1·6 
to 3·2)
3·4 (2·5 
to 4·4)
0·5 (0·5 to 
0·6)
1·0 (0·9 
to 1·2)
1·5 
(1·4 to 
1·7)
−3·9% 
(−5·1 to 
−2·5)
4·5% (2·6 
to 6·1)
−2·0% (−3 
·4 to 0·0)
−3·9% 
(−4·7 to 
−3·1)
 Bulgaria 28·1 
(22·9 to 
33·9)
100 
(66·9 to 
126)
128 
(93·7 to 
156)
12·5 (11·8 
to 13·3)
42·1 
(39·9 to 
44·3)
54·6 
(52·3 
to 
57·0)
1·5% (−2 5 
to 56·2)
3·3% (1·2 
to 4·8)
6·7% (6 4 to 
7·0)
−4·7% 
(−5·2 to 
−4·2)
 Croatia 10·9 
(5·5 to 
15·1)
34·1 
(17·9 to 
48·0)
44·9 
(23·6 to 
61·9)
2·1 (2·0 to 
2·3)
6·8 (6·5 
to 7·2)
9·0 
(8·7 to 
9·3)
1·7% (0·0 
to 3·2)
1·9% 
(−3·9 to 
6·0)
−2·6% (−2·9 
to −2·2)
6·7% 
(6·2 to 
7·3)
 Czech 
Republic
17·6 
(9·3 to 
28·4)
87·8 
(38·0 to 
148)
105 
(48·0 to 
165)
7·4 (6·9 to 
7·9)
16·4 
(15·6 to 
17·2)
23·7 
(22·9 
to 
24·6)
9·2% (8·0 
to 10·3)
2·8% 
(−3·7 to 
5·6)
3·9% (3·6 to 
4·2)
5·4% 
(4·9 to 
5·9)
 Hungary 28·8 
(17·5 to 
50·9)
99·4 
(63·4 to 
158)
128 
(86·0 to 
193)
8·1 (7·5 to 
8·7)
31·8 
(30·2 to 
33·7)
39·8 
(38·1 
to 
41·7)
−1·5% 
(−3·0 to 
0·2)
3·1% (1·2 
to 5·6)
−4·2% (−4·5 
to −3·8)
−7·6% 
(−8·2 to 
−7·0)
 Macedonia 4·0 (3·0 
to 5·2)
5·4 (4·0 
to 7 4)
9·3 (7·1 
to 12·2)
0·7 (0·5 to 
0·9)
1·0 (0·8 
to 1·1)
1·7 
(1·4 to 
2·0)
9·9% (7·6 
to 11·8)
1·8% 
(−0·7 to 
4·0)
8·6% (7·3 to 
10·1)
−2·2% 
(−4·2 to 
−0·9)
Montenegro
1·9 (1·4 
to 2·4)
4·7 (3·6 
to 6·2)
6·6 (5·1 
to 8·4)
0·6 (0·4 to 
0·9)
0·7 (0·6 
to 0·8)
1·4 
(1·1 to 
1·7)
3·9% (1·8 
to 5·7)
3·1% (1·0 
to 4·8)
4·9% (3·2 to 
6·3)
−2·8% 
(−6·1 to 
−0·0)
 Poland 151 
(78·7 to 
246)
532 
(239 to 
981)
683 
(319 to 
1220)
32 0 (30·2 
to 33·9)
112 
(106 to 
118)
144 
(138 to 
150)
5·2% (2·8 
to 7·6)
0·3% 
(−5·6 to 
2·7)
5·3% (5·0 to 
5·6)
−2·2% 
(−2·7to 
−1·6)
 Romania 258 
(185 to 
323)
591 
(417 to 
778)
849 
(634 to 
1050)
47·9 (45·1 
to 51·2)
118 
(112 to 
123)
165 
(160 to 
171)
10·0% (7·6 
to 12·6)
−0·1% 
(−2·4 to 
1·7)
−2·8% (−3·2 
to −2 4)
2·7% 
(2·1 to 
3·2)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Serbia 18·5 
(11·6 to 
30·9)
112 
(73·2 to 
181)
130 
(85·9 to 
209)
12·3 (6·2 to 
28·9)
60·2 
(23·9 to 
126)
72·5 
(30·3 
to 156)
8·3% (4·6 
to 60·9)
−4·5% 
(−7·3 to 
−1·6)
3·7% (−0·3 
to 54·4)
1·9% 
(−4·5 to 
6·9)
 Slovakia 6·5 (4·7 
to 8·3)
16·5 
(11·2 to 
25·2)
23·0 
(16·2 to 
33·5)
1·2 (0·8 to 
1·7)
2·7 (2·1 
to 3·3)
3·9 
(3·0 to 
4·9)
4·2% (−1·5 
to 48·2)
2·0% 
(−0·1 to 
4·3)
7·7% (4·1 to 
38·6)
−0·1% 
(−3·7 to 
2·0)
 Slovenia 1·6 (1·1 
to 2·5)
9·9 (6·7 
to 15·2)
11·5 
(7·9 to 
17·8)
0·4 (0·3 to 
0·4)
2·1 (2 ·0 
to 2·2)
2·5 
(2·4 to 
2·6)
−1·2% 
(−4·7 to 
48·3)
4·1% (2·3 
to 5·8)
−1·8% (−2·1 
to −1·4)
−4·8% 
(−5·3 to 
−4·2)
Eastern 
Europe
55500 
(46300 
to 
68700)
115000 
(90500 
to 
142000)
171000 
(139000 
to 
209000)
7730 (7650 
to 7820)
17400 
(17100 
to 
17600)
25100 
(24800 
to 
25300)
8·8% (7·6 
to 10·1)
12·4% 
(9·8 to 
14·3)
8·4% (8·3 to 
8·5)
2·1% 
(2·0 to 
2·3)
 Belarus 1280 
(781 to 
1930)
1260 
(935 to 
1680)
2540 
(1730 to 
3610)
94·1 (89·0 
to 99·4)
210 
(194 to 
226)
304 
(288 to 
320)
7·8% (0·9 
to 66·8)
9·8% (6·8 
to 12·6)
10·6% (10·1 
to 11·0)
0·3% 
(−0·4 to 
1·0)
 Estonia 41·6 
(30·5 to 
61·3)
165 
(119 to 
238)
207 
(152 to 
298)
7·8 (7·4 to 
8·2)
29·4 
(27·3 to 
31·7)
37·2 
(35·0 
to 
39·5)
27·4% 
(24·5 to 
30·8)
−1·8% 
(−5·3 to 
2·9)
25·5% (25·1 
to 25·9)
0·2% 
(−0·6 to 
1·1)
 Latvia 203 
(134 to 
238)
255 
(204 to 
313)
458 
(345 to 
528)
57·1 (54·4 
to 59·7)
69·4 
(64·8 to 
74·0)
126 
(121 to 
132)
4·0% (2·9 
to 4·9)
7·1% (3·8 
to 8·5)
5·5% (5·1 to 
5·9)
5·1% 
(4·5 to 
5·8)
 Lithuania 41·1 
(10·0 to 
61·9)
94·0 
(26·1 to 
146)
135 
(36·0 to 
196)
42·3 (40·3 
to 44·6)
24·7 
(23·1 to 
26·4)
67·0 
(64·5 
to 
69·7)
6·4% (4·3 
to 62·5)
−0·1% 
(−12 3 to 
2·7)
9·2% (8·9 to 
9·6)
0·6% 
(0·0 to 
1·2)
 Moldova 377 
(267 to 
548)
398 
(287 to 
560)
775 
(569 to 
1080)
49·5 (46·8 
to 52·1)
124 
(116 to 
132)
173 
(164 to 
182)
8·5% (0·9 
to 14·6)
1·8% 
(−0·5 to 
3·6)
10·7% (10·2 
to 11·1)
−3·1% 
(−3·9 to 
−2 4)
 Russia 41700 
(34600 
to 
51600)
97100 
(78500 
to 
122000)
139000 
(115000 
to 
171000)
5480 (5430 
to 5520)
13800 
(13700 
to 
14000)
19300 
(19100 
to 
19500)
10·0% (8·8 
to 12·3)
13·2% 
(10·3 to 
15·5)
7·0% (6·9 to 
7·0)
5·9% 
(5·8 to 
6·0)
 Ukraine 11800 
(7920 to 
16500)
16100 
(9210 to 
20500)
27900 
(19000 
to 
35300)
2000 (1930 
to 2080)
3070 
(2930 to 
3220)
5080 
(4920 
to 
5240)
5·9% (2·8 
to 8·1)
9·7% (6·9 
to 12·6)
10·7% (10·5 
to 11·0)
−5·9% 
(−6·3 to 
−5·5)
High-income 34600 
(19800 
to 
51000)
88600 
(52700 
to 
130000)
123000 
(72600 
to 
179000)
3750 (3720 
to 3790)
10200 
(10100 
to 
10300)
13900 
(13800 
to 
14000)
−1·8% 
(−3·1 to 
−0·4)
2·0% 
(−0·2 to 
3·2)
−5·0% 
(−5·1 to 
−5·0)
−4·9% 
(−4·9 to 
−4·8)
Australasia 417 
(228 to 
745)
1160 
(691 to 
1760)
1580 
(950 to 
2270)
20·6 (19·8 
to 21·4)
65·9 
(63·8 to 
68·1)
86·6 
(84·4 
to 
88·9)
−0·3% 
(−2·8 to 
1·9)
2·5% (1·2 
to 4·0)
−8·4% (−8·7 
to −8·2)
−5·9% 
(−6·2 to 
−5·6)
 Australia 378 
(202 to 
698)
1020 
(591 to 
1560)
1390 
(834 to 
2030)
18·7 (17·9 
to 19·5)
57·9 
(55·8 to 
60·0)
76·6 
(74·4 
to 
78·9)
−1·0% 
(−3·7 to 
1·4)
2·8% (1·5 
to 4·3)
−8·2% (−8·4 
to −7·9)
−6·3% 
(−6·7 to 
−6·0)
 New 
Zealand
38·9 
(20·7 to 
59·8)
147 
(68·4 to 
233)
186 
(89·6 to 
293)
1·9 (1·9 to 
2·0)
8·1 (7·8 
to 8·3)
10·0 
(9·7 to 
10·3)
5·7% (4·1 
to 8·9)
0·6% 
(−4·2 to 
3·7)
−10·4% 
(−10·7 to 
−10·2)
−2·6% 
(−3·0 to 
−2 2)
High-income 
Asia Pacific
669 
(396 to 
955)
2310 
(1240 to 
3660)
2970 
(1680 to 
4530)
79·9 (78·1 
to 81·9)
312 
(302 to 
322)
392 
(382 to 
402)
5·0% (2·4 
to 8·5)
0·2% 
(−4·5 to 
2·7)
4·5% (4·3 to 
4·7)
−2·2% 
(−2·5 to 
−1·9)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Brunei 7·9 (4·3 
to 12·8)
27·8 
(15·1 to 
45·9)
35·7 
(19·8 to 
57·7)
1·4 (1·1 to 
1·6)
3·3 (2·8 
to 3·9)
4·7 
(4·0 to 
5·4)
5·3% (3·9 
to 6·6)
3·7% (0·4 
to 5·8)
6·4% (5·0 to 
8·0)
−1·6% 
(−3·9 to 
0·3)
 Japan 426 
(212 to 
624)
1040 
(501 to 
1510)
1460 
(724 to 
2130)
59·4 (58·1 
to 60·6)
147 
(144 to 
151)
207 (2 
03 to 
210)
4·4% (2·8 
to 6·1)
1·9% 
(−2·1 to 
3·5)
5·8% (5·8 to 
6·0)
−2·9% 
(−3·0 to 
−2 7)
 Singapore 56·0 
(22·3 to 
90·6)
113 
(62·9 to 
196)
169 
(90·1 to 
268)
3·1 (2·8 to 
3·5)
29·6 
(27·5 to 
31·7)
32·7 
(30·6 
to 
34·9)
−5·6% 
(−8·1 to 
−4·0)
−1·1% 
(−3·8 to 
1·6)
7·5% (6·9 to 
8·1)
−6·7% 
(−7·7 to 
−5·8)
 South 
Korea
180 
(50·8 to 
296)
1130 
(273 to 
2280)
1310 
(327 to 
2530)
16·1 (14·9 
to 17·4)
131 
(122 to 
142)
148 
(138 to 
157)
8·3% (1·7 
to 62·6)
−2·6% 
(−13·6 to 
2·2)
1·0% (0·5 to 
1·4)
−0·7% 
(−1·5 to 
0·1)
High-income 
North 
America
15 600 
(6270 to 
24 700)
39 200 
(16100 
to 62 
300)
54 800 
(22 600 
to 86 
200)
2140 (2110 
to 2170)
5480 
(5400 to 
5550)
7620 
(7540 
to 
7690)
−2·3% 
(−3·8 to 
0·9)
1·6% 
(−4·7 to 
3·6)
−6·2% (−6·2 
to −6·1)
−6·0% 
(−6·2 to 
−5·9)
 Canada 942 
(434 to 
1490)
2590 
(1050 to 
4310)
3530 
(1520 to 
5660)
72·2 (68·5 
to 76·3)
202 
(189 to 
215)
274 
(261 to 
2 87)
−1·8% 
(−3·5 to 
1·9)
3·9% 
(−1·7 to 
6·8)
−4·8% (−5·1 
to −4·6)
−5·6% 
(−6·2 to 
−5·0)
 Greenland 6·2 (2·2 
to 11·1)
4·7 (2·1 
to 7·7)
10·9 
(4·6 to 
18·1)
0·8 (0·6 to 
1·0)
0·9 (0·6 
to 1·1)
1·6 
(1·3 to 
2 0)
−0·8% 
(−2·5 to 
2·2)
4·2% 
(−2·2 to 
6·6)
0·1% (−1·3 
to 1·7)
−5·0% 
(−7·6 to 
−3·4)
 USA 14700 
(5440 to 
23600)
36600 
(14300 
to 
58900)
51300 
(19700 
to 
81300)
2070 (2040 
to 2100)
5270 
(5200 to 
5340)
7340 
(7260 
to 
7420)
−2·3% 
(−3·9 to 
1·0)
1·5% 
(−5·6 to 
3·6)
−6·2% (−6·3 
to −6·2)
−6·0% 
(−6·2 to 
−5·9)
Southern 
Latin 
America
6630 
(3020 to 
12300)
10500 
(5830 to 
17100)
17100 
(9040 to 
28300)
673 (657 to 
690)
1730 
(1700 to 
1770)
2400 
(2370 
to 
2440)
1·7% (0·3 
to 3·2)
1·8% (0·8 
to 3·0)
5·0% (4·9 to 
5·1)
−0·9% 
(−1·1 to 
−0 7)
 Argentina 5750 
(2490 to 
11300)
6430 
(3330 to 
10900)
12 200 
(6000 to 
21000)
548 (533 to 
565)
1170 
(1140 to 
1200)
1720 
(1680 
to 
1750)
1·0% (−0·6 
to 2·6)
1·0% 
(−0·3 to 
2·7)
4·7% (4·6 to 
4·8)
−1·4% 
(−1·7 to 
−1·2)
 Chile 682 
(339 to 
1180)
3440 
(1850 to 
5490)
4120 
(2220 to 
6690)
85·3 (829 to 
87 7)
419 
(407 to 
430)
505 
(493 to 
516)
5·0% (3·8 
to 6·2)
3·7% (2·8 
to 4 7)
6·3% (6·1 to 
6·5)
0·6% 
(0·3 to 
0·9)
 Uruguay 193 
(131 to 
279)
635 
(527 to 
781)
828 
(671 to 
1040)
39·8 (38·8 
to 40·8)
141 
(137 to 
144)
181 
(177 to 
184)
0·4% (−6·0 
to 4·8)
5·9% (3·5 
to 8·5)
7·1% (7·0 to 
7·3)
−0·5% 
(−0·8 to 
−0·2)
Western 
Europe
11200 
(6590 to 
16200)
35500 
(21200 
to 
51600)
46700 
(27800 
to 
67200)
836 (818 to 
856)
2610 
(2550 to 
2670)
3450 
(3390 
to 
3510)
−2·7% 
(−4·8 to 
−1·1)
2·0% (0·2 
to 3·4)
−4·9% (−5·0 
to −4·8)
−5·4% 
(−5·6 to 
−5·2)
 Andorra 0·6 (0·0 
to 2·8)
4·0 (0·2 
to 19·1)
4·6 (0·3 
to 21·4)
0·1 (0·0 to 
0·4)
0·3 (0·0 
to 1·5)
0·4 
(0·0 to 
1·9)
−0·6% 
(−11·1 to 
7·0)
0·4% 
(−6·3 to 
7·3)
−3·6% 
(−10·2 to 
1·4)
−8·5% 
(−12·8 
to −3·2)
 Austria 169 
(93·4 to 
248)
518 
(273 to 
798)
688 
(369 to 
1030)
8·5 (8·0 to 
9·0)
29·5 
(27·9 to 
31·2)
38·0 
(36·3 
to 
39·8)
−0·0% 
(−6·1 to 
65·4)
0·8% 
(−2·0 to 
4·5)
−2·0% (−2·4 
to −1·6)
−4·7% 
(−5·4 to 
−4·1)
 Belgium 350 
(153 to 
541)
787 
(298 to 
1310)
1140 
(444 to 
1850)
20·0 (19·0 
to 21·2)
41·8 
(39·7 to 
44·3)
61·9 
(59·4 
to 
64·7)
1·6% (−0·9 
to 3·6)
−0·2% 
(−6·0 to 
3·4)
−4·3% (−4·6 
to −4·0)
−2·5% 
(−3·0 to 
−1·9)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Cyprus 15·2 
(10·4 to 
21·0)
96·0 
(68·3 to 
138)
111 
(79·5 to 
158)
0·4 (0·4 to 
0·5)
1·4 (1·2 
to 1·7)
1·9 
(1·6 to 
2·1)
6·1% (3·6 
to 9·2)
5·0% (2·7 
to 7·6)
4·4% (2 5 to 
6·0)
−3·7% 
(−5·2 to 
−2 1)
 Denmark 155 
(53·8 to 
264)
253 
(125 to 
457)
408 
(206 to 
643)
7·7 (7·2 to 
8·2)
19·2 
(18·1 to 
20·2)
26·9 
(25·8 
to 
28·1)
−2·3% 
(−4·0 to 
−0·8)
1·1% 
(−5·0 
to3·8)
−5·9% (−6·3 
to −5·5)
−3·4% 
(−4·1 to 
−2·9)
 Finland 34·5 
(9·7 to 
59·1)
127 
(34·0 to 
223)
161 
(43·7 to 
280)
1·7 (1·6 to 
1·8)
4·8 (4·5 
to 5·1)
6·5 
(6·2 to 
6·8)
2·6% (0·5 
to 4 7)
−1·2% 
(−10 7 to 
4·0)
−0·2% (−0·6 
to 0·1)
−10·2% 
(−10·8 
to −9·6)
 France 1620 
(734 to 
2880)
3570 
(1660 to 
6480)
5190 
(2670 to 
8610)
134 (126 to 
142)
358 
(337 to 
380)
491 
(469 to 
514)
−3·1% 
(−6·1 to 
−1·1)
0·3% 
(−1·6 to 
2·0)
−8·7% (−8·9 
to −8·5)
−6·1% 
(−6·7 to 
−5·6)
 Germany 1460 
(884 to 
2050)
4980 
(2920 to 
7180)
6430 
(3810 to 
9130)
102 (96·3 to 
107)
363 
(345 to 
381)
465 
(446 to 
483)
1·3% (−0·2 
to 2·2)
2·7% 
(−0·2 to 6 
7)
−7·0% (−7·2 
to −6·7)
−2·5% 
(−3·0 to 
−2·1)
 Greece 54·8 
(35·3 to 
75·5)
459 
(280 to 
805)
514 
(326 to 
854)
6·0 (5·6 to 
6·4)
23·6 
(22·3 to 
24·8)
29·6 
(28·2 
to 
30·9)
1·9% (−0·1 
to 4·0)
0·1% 
(−2·1 to 
2·6)
−4·0% (−4·4 
to −3·6)
3·3% 
(2·7 to 
3·9)
 Iceland 0·0 (0·0 
to 0·1)
20·1 
(8·9 to 
30·3)
20·1 
(8·9 to 
30·3)
0·0 (0·0 to 
0·0)
0·8 (0·8 
to 0·9)
0·9 
(0·8 to 
0·9)
−0·1% 
(−2·5 to 
1·9)
−1·2% 
(−8·5 to 
3·0)
−4·3% (−4·8 
to −4·0)
−4·4% 
(−5·2 to 
−3 7)
 Ireland 148 
(56·6 to 
225)
414 
(153 to 
665)
562 
(206 to 
884)
2·7 (2·5 to 
2·9)
7·1 (6·7 
to 7·6)
9·8 
(9·3 to 
10·3)
−0·9% 
(−2·8 to 
0·9)
4·1% 
(−4·3 to 
6·8)
−0·5% (−0·9 
to −0·1)
−5·4% 
(−6·0 to 
−4 7)
 Israel 202 
(106 to 
288)
485 
(253 to 
695)
688 
(377 to 
970)
12·8 (12·2 
to 13·5)
28·6 
(27·1 to 
30·1)
41·4 
(39·8 
to 
43·0)
3·1% (0·6 
to 5·8)
0·0% 
(−4·8 to 
4·8)
−1·2% (−1·5 
to −0·9)
−4·7% 
(−5·3 to 
−4·2)
 Italy 1580 
(962 to 
2300)
5560 
(3360 to 
8330)
7140 
(4260 to 
10600)
156 (146 to 
166)
505 
(479 to 
533)
661 
(634 to 
692)
−5·5% 
(−11·6 to 
2·7)
3·7% (0·8 
to 7·0)
−5·3% (−5·6 
to −5·1)
−5·1% 
(−5·6 to 
−4·6)
Luxembourg
19·7 
(9·6 to 
28·9)
75·9 
(31·9 to 
115)
95·6 
(41·5 to 
141)
0·6 (0·6 to 
0·7)
1·8 (1·7 
to 1·9)
2·4 
(2·3 to 
2·5)
−3·7% 
(−5·6 to 
−2·3)
2·5% 
(−4·8 to 
5·9)
−4·8% (−5·2 
to −4·3)
−4·8% 
(−5·5 to 
−4·2)
 Malta 16·7 
(9·1 to 
23·9)
81·7 
(43·7 to 
133)
98·4 
(53·3 to 
155)
0·4 (0·4 to 
0·5)
1·2 (1·1 
to 1·3)
1·6 
(1·6 to 
1·7)
3·7% (1·6 
to 5·1)
9·1% (7·7 
to 10·2)
−2·1% (−2 5 
to −1·8)
−2·7% 
(−3·4 to 
−2 0)
Netherlands
187 
(95·1 to 
283)
344 
(166 to 
526)
531 
(260 to 
804)
17·1 (16·1 
to 18·1)
38·5 
(36·5 to 
40·7)
55·5 
(53·3 
to 
58·0)
3·9% (2·5 
to 5·2)
−7·3% 
(−13·2 to 
−3·3)
−8·5% (−8·8 
to −8·2)
−4·7% 
(−5·3 to 
−4·2)
 Norway 95·3 
(50·8 to 
141)
197 
(99·0 to 
300)
292 
(150 to 
441)
4·3 (4·2 to 
4·4)
10·5 
(10·2 to 
10 7)
14·8 
(14·5 
to 
15·1)
−1·0% 
(−3·4 to 
0·9)
0·7% 
(−2·8 to 
3·6)
−5·2% (−5·4 
to −5·0)
−1·0% 
(−1·3 to 
−0·8)
 Portugal 1550 
(776 to 
2320)
6080 
(2930 to 
9150)
7630 
(3730 to 
11200)
108 (102 to 
115)
394 
(372 to 
418)
502 
(479 to 
528)
2·5% (−0·5 
to 5·3)
2·5% 
(−2·1 to 
6·1)
7·9% (7·6 to 
8·2)
−6·2% 
(−6·8 to 
−5·7)
 Spain 1150 
(464 to 
2120)
5380 
(2160 to 
9960)
6530 
(2820 to 
11800)
146 (136 to 
157)
563 
(531 to 
598)
708 
(675 to 
743)
−10·3% 
(−12·1to 
−8·6)
5·8% (1·8 
to 8·4)
−4·7% (−5·0 
to −4·5)
−7·3% 
(−7·9to 
−6·8)
 Sweden 243 
(109 to 
379)
383 
(185 to 
593)
626 
(305 to 
962)
8·2 (7·8 to 
8·6)
14·6 
(14·0 to 
15·1)
22·8 
(22·1 
−5·1% 
(−7·3 to 
−3·5)
1·5% 
(−3·9 to 
3·6)
−4·6% (−4·8 
to −4·3)
−5·3% 
(−5·7 to 
−5·0)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
to 
23·4)
Switzerland
194 
(74·5 to 
288)
460 
(152 to 
704)
654 
(226 to 
987)
10·5 (9·9 to 
11·1)
27·9 
(26·4 to 
29·6)
38·3 
(36·7 
to 
40·2)
−7·0% 
(−9·3 to 
−4·0)
−0·1% 
(−6·7 to 
2·1)
−7·0% (−7·4 
to −6·6)
−6·4% 
(−7·0 to 
−5·8)
 UK 1950 
(1120 to 
2800)
5200 
(3010 to 
7410)
7150 
(4110 to 
10100)
89·2 (88·5 
to 89·9)
175 
(174 to 
176)
264 
(263 to 
266)
3·7% (1·7 
to 5·1)
1·1% 
(−0·8 to 
2·5)
−2·4% 
(−2·5to 
−2·4)
−3·9% 
(−3·9 to 
−3·8)
Latin 
America and 
Caribbean
52 200 
(44 900 
to 
60600)
110 000 
(94 300 
to 
129000)
162000 
(140000 
to 
188000)
14100 (12 
800 to 
16400)
28400 
(26 700 
to 
31100)
42 500 
(39 
800 to 
47300)
−0·5% 
(−1·8 to 
0·6)
2·1% 
(0·6 to 
3·2)
4·1% (3·3 
to 4·5)
−2·9% 
(−3·4 to 
−2·1)
Andean Latin 
America
3950 
(2520 to 
6980)
8440 
(5850 to 
13200)
12400 
(8420 to 
19800)
1600 (803 
to 3610)
3060 
(1830 to 
5640)
4660 
(2 630 
to 
9190)
5·6% (1·5 
to 8·4)
2·0% 
(−0·2 to 
4·5)
6·6% (3·1 to 
9·6)
0·9% 
(−2·8 to 
4·6)
 Bolivia 905 
(77·5 to 
3880)
1590 
(168 to 
5750)
2490 
(260 
to9880)
458 (11·3 to 
2490)
709 
(31·3 to 
3220)
1170 
(46·3 
to 
5690)
0·2% 
(−10·4 to 
8·7)
2·3% 
(−4·8 to 
7·0)
4·0% (−4·3 
to 15·5)
0·5% 
(−20·2 
to 7·9)
 Ecuador 1050 
(708 to 
1410)
2060 
(1740 to 
2580)
3100 
(2500 to 
3980)
271 (252 to 
293)
822 
(775 to 
874)
1090 
(1040 
to 
1150)
9·2% (4·5 
to 12 0)
1·4% (0·2 
to 2·6)
11·9% 
(11·6to12·2)
0·4% 
(−0·2 to 
1·0)
 Peru 1990 
(1390 to 
3030)
4790 
(3320 
to7700)
6780 
(4730 to 
10 600)
868 (430 to 
1320)
1530 
(830 to 
2370)
2400 
(1270 
to 
3710)
7·1% (5·1 
to 8·4)
2·0% 
(−0·9 to 
5·7)
6·4% (5·0 
to7·9)
1·1% 
(−3·7 to 
4·0)
Caribbean 8830 
(6730 to 
11000)
9990 
(8020 to 
12 200)
18800 
(15 600 
to 
22300)
3460 (2670 
to 4410)
5100 
(4300 to 
6200)
8560 
(7470 
to 
9950)
−4·4% 
(−5·8 to 
−2·9)
−2·5% 
(−4·1 to 
−0·9)
6·5% (4·1 to 
8·1)
−7·5% 
(−8·4 to 
−6·6)
 Antigua 
and Barbuda
2·6 (2 1 
to 3·4)
6·3 (5·3 
to 8·2)
8·9 (7·5 
to 11·6)
2·3 
(2·2to2·3)
5·2 (5·1 
to 5·4)
7·5 
(7·4 to 
7·6)
−6·8% 
(−8·4 to 
−5·6)
2·7% (0·4 
to 5·8)
−2·6% (−2·8 
to −2·5)
−0·8% 
(−1·1 to 
−0·6)
 The 
Bahamas
137 
(115 to 
186)
227 
(186 to 
286)
365 
(321 to 
463)
47·2 (46·1 
to 48·5)
67·0 
(65·3 to 
68·8)
114 
(112 to 
116)
−3·2% 
(−4·2 to 
−1·9)
3·4% (2·4 
to 5·0)
1·8% 
(1·6to2·0)
−3·0% 
(−3·3 to 
−2·8)
 Barbados 26·1 
(18·7 to 
37·2)
43·2 
(30·3 to 
61·5)
69·3 
(49·6 to 
98·4)
8·8 (8·6 to 
8·9)
16·2 
(15·9 to 
16·6)
25·0 
(24·6 
to 
25·4)
−1·5% 
(−2·6 to 
1·0)
−0·6% 
(−4·0 to 
3·2)
−1·9% 
(−2·1to 
−1·8)
−3·6% 
(–3·9 to 
−3·4)
 Belize 113 
(86·6 to 
148)
138 
(122 to 
167)
251 
(210 to 
313)
28·6 (27·9 
to 29·3)
52·6 
(51·2 to 
53·9)
81·2 
(79·5 
to 
82·6)
0·3% (−1·0 
to 1·8)
3·7% (2 5 
to 5·2)
0·3% (0·1 to 
0·5)
−1·1% 
(−1·4 to 
−0·9)
 Bermuda 1·4 (1·2 
to 1·6)
4·4 (3·9 
to 5·0)
5·8 (5·1 
to 6·6)
1·6 (1·5 to 
1·6)
5·3 (5·2 
to 5·4)
6·8 
(6·7 to 
7·0)
−8·3% 
(−9·5 to 
−7·5)
1·0% 
(−0·8 to 
3·4)
−4·6% (−4·7 
to −4·4)
−2·0% 
(−2 3 to 
−1·7)
 Cuba 684 
(295 to 
1180)
2130 
(1140 to 
3350)
2810 
(1540 to 
4330)
58·6 (57·3 
to 60·0)
303 
(295 to 
310)
361 
(354 to 
369)
11·5% (9·8 
to 13·1)
5·8% (4·1 
to 7·3)
4·5% (4·4 to 
4·7)
7·7% 
(7·5 to 
8·0)
 Dominica 2·0 (1·4 
to 3·2)
4·7 (3·8 
to 6·2)
6·6 (5·3 
to 9·4)
1·2 (1·2 to 
1·2)
3·9 (3·8 
to 3·9)
5·0 
(4·9 to 
5·1)
−5·3% 
(−6·4 to 
−4·4)
1·8% 
(−0·1 to 
4·4)
−1·4% 
(−1·6to 
−1·2)
−1·0% 
(−1·3 to 
−0·7)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Dominican 
Republic
1740 
(787 to 
2930)
2220 
(1210 to 
3600)
3960 
(2410 to 
6000)
853 (332 to 
1510)
1710 
(1140 to 
2520)
2560 
(1800 
to 
3630)
0·2% (−2 4 
to 3·0)
−3·1% 
(−5·7to 
−0·5)
21·5% (17·9 
to 24·9)
−6·2% 
(−8·1 to 
−4·5)
 Grenada 1·9 (1·4 
to 2·6)
4·6 (4·0 
to 5·7)
6·5 (5·5 
to 8·2)
1·7 
(1·6to1·7)
4·5 (4·4 
to 4·6)
6·2 
(6·0 to 
6·3)
−6·2% 
(−7·6to 
−5·0)
−0·1% 
(−1·8 to 
2·1)
−2·8% (−3·0 
to −2 7)
−0·8% 
(−1·1 to 
−0·5)
 Guyana 335 
(236 to 
426)
265 
(190 to 
354)
600 
(431 to 
756)
79·4 (77·6 
to 81·2)
116 
(113 to 
120)
196 
(192 to 
199)
5·0% (1·2 
to 8·1)
−4·2% 
(−5·7 to 
−2·3)
5·9% (5·7 to 
6·0)
−3·4% 
(−3·7 to 
−3·2)
 Haiti 4590 
(2990 to 
6280)
3320 
(2170 to 
4910)
7910 
(5770 to 
10 500)
1860 (1290 
to 2550)
1990 
(1570 to 
2720)
3850 
(3150 
to 
4870)
−8·5% 
(−10·1 to 
−6·5)
−6·1% 
(−8·3 to 
−4·2)
6·4% (2·5 to 
9·7)
−12·6% 
(−14·0 
to 
−11·2)
 Jamaica 529 
(369 to 
759)
751 
(590 to 
968)
1280 
(965 to 
1700)
187 (182 to 
191)
253 
(247 to 
259)
440 
(432 to 
447)
−0·5% 
(−5·6to2·9)
1·2% 
(−1·6 to 
3·7)
3·3% (3·2 to 
3·5)
−2·4% 
(−2·6 to 
−2·1)
 Puerto 
Rico
53·7 
(45·2 to 
62·8)
144 
(118 to 
171)
198 
(165 to 
231)
66·8 
(65·3to68·4)
171 
(167 to 
176)
238 
(234 to 
243)
−14·6% 
(−16·0 to 
−13·7)
2·8% (1·1 
to 5·0)
−5·7% (−5·8 
to −5·5)
−5·9% 
(−6·2 to 
−5·6)
 Saint Lucia 3·4 (2 7 
to 4·8)
5·4 (4·5 
to 7·1)
8·8 (7·3 
to 11·7)
2·9 (2·8 to 
3·0)
4·9 (4·8 
to 5·1)
7·8 
(7·7 to 
8·0)
−6·8% 
(−8·1 to 
−5·7)
1·6% 
(−0·5 to 
4·3)
−2·2% 
(−2·3to 
−2·0)
−2·5% 
(−2·7to 
−2·2)
 Saint 
Vincent 
andthe 
Grenadines
7·2 (5·9 
to 9·7)
13·7 
(11·6 to 
17·5)
20·9 
(17·6to2
7·0)
6·8 (6·6 to 
7·0)
13·3 
(13·0 to 
13·7)
20·1 
(19·8 
to 
20·5)
−6·2% 
(−8·1 to 
−4·4)
1·2% 
(−0·7 to 
3·8)
0·8% (0·7 to 
1·0)
−2·3% 
(−2 5 to 
−2·0)
 Suriname 93·8 
(74·7 to 
127)
114 
(91·2 to 
148)
207 
(169 to 
271)
40·2 (39·3 
to 41·2)
61·6 
(60·0 to 
63·1)
102 
(99·9 
to 104)
−0·7% 
(−4·6 to 
3·7)
0·2% 
(−1·9 to 
3·1)
1·9% (1·8 to 
2·1)
−3·9% 
(−4·1 to 
−3·6)
 Trinidad 
and Tobago
187 
(151 to 
250)
227 
(192 to 
280)
414 
(354 to 
512)
83·8 
(81·6to85·9)
136 
(132 to 
139)
219 
(216 to 
224)
−1·0% 
(−2·9to1·5)
−1·1% 
(−2·7to0·
9)
4·3% (4·2 to 
4·5)
−2·3% 
(−2·6to 
−2·1)
 Virgin 
Islands
3·9 (2·8 
to 5·9)
10·7 
(7·2 to 
17·0)
14·7 
(10·1 to 
22·8)
3·0 (2·9 to 
3·0)
6·0 (5·8 
to 6·2)
9·0 
(8·8 to 
9·1)
−4·1% 
(−8·2 to 
−1·5)
4·4% (1·4 
to 7·4)
0·3% (0·1 to 
0 4)
−0·6% 
(−0·9 to 
−0 4)
Central Latin 
America
10500 
(7800 to 
14100)
35300 
(27 800 
to 
45900)
45800 
(35 700 
to 
58900)
3330 (3140 
to 3480)
9770 
(9420 to 
10100)
13100 
(12 
600 to 
13500)
−0·9% (−2 
·4to0·6)
2·7% (1·0 
to 4·2)
4·6% (4·5 to 
4·8)
−1·8% 
(−2·2 to 
−1·6)
 Colombia 2430 
(1640 to 
3480)
7090 
(5400 to 
9580)
9520 
(7040 to 
12 900)
661 (627 to 
697)
1980 
(1890 to 
2070)
2640 
(2530 
to 
2740)
2·9% 
(0·4to5·4)
5·0% 
(2·4to7·6)
8·4% (8·1 to 
8·7)
−2·3% 
(−2·8 to 
−1·9)
 Costa Rica 91·4 (62 
4to121)
295 
(217 to 
406)
386 
(283 to 
526)
38·5 (36·5 
to 40·6)
115 
(108 to 
122)
153 
(146 to 
160)
0·9% (0·1 
to 1·9)
−1·5% 
(−3·9 to 
0·3)
2·2% (1·9 to 
2·6)
−0·4% 
(−0·9 to 
0·2)
 El 
Salvador
458 
(276 to 
660)
789 
(487 to 
1080)
1250 
(770 to 
1690)
247 (86·2 to 
378)
481 
(235 to 
685)
728 
(320 to 
1050)
7·1% (3·0 
to 10·5)
−4·9% 
(−7·7to 
−2·4)
11·5% 
(9·9to12·9)
−1·0% 
(−6·9 to 
1·3)
 Guatemala 830 
(375 to 
1910)
1480 
(709 to 
3230)
2310 
(1100 to 
5120)
228 (217 to 
240)
472 
(449 to 
496)
700 
(676 to 
727)
2·7% (−2·8 
to 6·8)
−1·2% 
(−6·9 to 
3·7)
3·2% (2·9 to 
3·5)
−5·4% 
(−5·9 to 
−5·0)
 Honduras 211 
(127 to 
334)
268 
(179 to 
393)
479 
(320 to 
683)
25·4 (17·4 
to 39·1)
37·5 
(29·1 to 
47·8)
62·9 
(47·0 
0·5% (−1·9 
to 2·7)
−3·0% 
(−7·1 to 
0·3)
−0·9% (−3·2 
to 3·2)
−8·2% 
(−11·8 
to −4·8)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
to 
83·2)
 Mexico 3930 
(2930 to 
5560)
15900 
(11700 
to 
21400)
19800 
(14 600 
to 
26000)
1250 (1230 
to 1260)
4330 
(4270 to 
4380)
5580 
(5520 
to 
5630)
−3·8% 
(−5·2 to 
−2·4)
2·8% (0·7 
to 4·8)
3·7% (3·6 to 
3·8)
−2·4% 
(−2·5to 
−2·2)
 Nicaragua 718 
(490 to 
1030)
1240 
(794 to 
1750)
1960 
(1320 to 
2680)
195 (103 to 
275)
395 
(229 to 
582)
590 
(333 to 
835)
14·3% (10 
7 to 16·5)
6·1% (3·1 
to 9·1)
11·3% 
(9·8to12·8)
9·5% 
(4·6to1
3·4)
 Panama 426 
(338 to 
538)
1440 
(1120 to 
2000)
1870 
(1490 to 
2510)
128 (121 to 
135)
398 
(377 to 
420)
526 
(505 to 
548)
−1·0% 
(−2·2 to 
0·8)
4·8% 
(3·3to6·5)
3·4% (3·0 to 
3·8)
−1·0% 
(−1·6to 
−0·5)
 Venezuela 1370 
(979 to 
1930)
6830 
(5480 to 
8270)
8200 
(6490 to 
10100)
557 (522 to 
593)
1570 
(1480 to 
1670)
2130 
(2030 
to 
2230)
3·9% (3·0 
to 5·2)
2·8% (0·9 
to 4·5)
3·1% (2·9 to 
3·3)
−0·1% 
(−0 7 to 
0 4)
Tropical 
Latin 
America
29000 
(20 800 
to 
35000)
56000 
(41500 
to 
66700)
85000 
(62 600 
to 
101000)
5720 (5530 
to 5880)
10500 
(10 200 
to 
10700)
16200 
(15 
700 to 
16500)
2·7% (1·2 
to 4·0)
3·4% (1·8 
to 4·2)
1·7% (1·6 to 
1·9)
−0·9% 
(−1·2 to 
−0 7)
 Brazil 28400 
(20 400 
to 
34300)
55000 
(40 700 
to 
65400)
83300 
(61500 
to 
99100)
5430 (5330 
to 5540)
9970 
(9800 to 
10100)
15400 
(15 
200 to 
15 
600)
2·6% (1·1 
to 3·9)
3·5% (1·9 
to 4·3)
1·6% (1·5 to 
1·7)
−1·2% 
(−1·4 to 
−1·0)
 Paraguay 638 
(412 to 
896)
1000 
(648 to 
1350)
1640 
(1070 
to2220)
283 (140 to 
397)
478 
(261 to 
666)
762 
(412 to 
1060)
11·8% (4·3 
to 16·4)
−0·1% 
(−2 7to2 
4)
11·9% (9·5 
to 16·0)
5·4% 
(1·2 to 
8 7)
North Africa 
and Middle 
East
8300 
(4650 to 
15 300)
9240 
(5490 to 
18 900)
17 500 
(10 700 
to 32 
500)
4690 (3410 
to 6700)
4750 
(3380 
to 
7020)
9440 
(7180 
to 13 
100)
4·2% (1·4 
to 7·7)
−0·4% 
(−4·0 to 
3·0)
10·5% (8·1 
to 12 7)
0·5% 
(−1·6 to 
2 4)
Afghanistan
353 
(12·2 to 
1650)
569 
(26·6 to 
2360)
922 
(41·7to3
660)
108 (1·3 to 
592)
194 (3 4 
to 961)
302 
(5·7 to 
1450)
2·0% 
(−8·6to12·
2)
8·4% 
(−2·2 to 
16·0)
4·3% (−4·5 
to 14·9)
2·6% 
(−21·8 
to 11·3)
 Algeria 396 (4·8 
to 1800)
505 (6·2 
to 1970)
901 
(11·1 to 
3490)
130 
(8·6to988)
197 (7·2 
to 939)
327 
(14·9 
to 
1860)
8·7% (2 3 
to 14·1)
−1·0% 
(−42·9 to 
7·8)
8·9% 
(1·7to13·1)
−2·2% 
(−17·4 
to 4·7)
 Bahrain 4·6 (3·8 
to 5·9)
15·5 
(13·2 to 
18 4)
20·2 
(17·3 to 
23·9)
3·0 (2 4 to 3 
7)
8·5 (7 4 
to 10·0)
11·5 
(9·8 to 
13·6)
−4·3% 
(−6·1 to −2 
7)
−0·6% 
(−1·9 to 
1·0)
1·8% (0·9 to 
3·1)
−6·4% 
(−7·5 to 
−5·4)
 Egypt 154 
(111 to 
223)
403 
(261 to 
552)
557 
(394 to 
723)
22·5 
(14·3to39·9)
42·3 (2 
8 7 to 
62·7)
64·8 
(45·6to
92·3)
0·6% 
(−1·7to2 7)
6·8% (3·5 
to 9·3)
1·3% (−0·6 
to 4·6)
−7·2% 
(−10·2 
to −3·6)
 Iran 1540 
(937 to 
2200)
1610 
(1110 to 
2270)
3150 
(2130 to 
4190)
322 (273 to 
371)
470 
(428 to 
521)
792 
(707 to 
889)
8·7% (1·1 
to 14·5)
10·3% 
(6·7 to 
12·5)
10·2% 
(9·3to11·4)
5·3% 
(4·2 to 
6·4)
 Iraq 124 
(61·7 to 
241)
104 (52 
3 to 
201)
229 
(115 to 
443)
60·6 (41·0 
to 94·3)
55·1 
(36·1 to 
86·5)
116 
(77·9 
to 181)
4·9% (0 
·4to8·1)
5·0% 
(0·6to9·1)
9·3% 
(6·6to11·6)
2·7% 
(−1·0 
to5·9)
 Jordan 18·5 
(12·3to2
6·7)
35·2 
(23·9 to 
47·1)
53·7 
(37·1 to 
69 7)
8·5 (7·1 to 
9·9)
14·5 
(9·1 to 
20 7)
22·9 
(16·9 
to 29 
7)
5·8% (2·8 
to 8·2)
1·1% 
(−2·1 to 3 
7)
6·9% (6·0 to 
8·1)
2·6% 
(−1·5 to 
5·4)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Kuwait 4·8 (4·0 
to 6·4)
10·6 
(7·9 to 
13·5)
15·4 
(12·3to1
9·2)
2·9 (2 4 to 
3·4)
2·5 (2·3 
to 2·8)
5·4 
(4·9 to 
6·0)
−3·1% 
(−5·0 to 
−1·7)
1·4% 
(−1·3 to 
4·0)
−2·2% (−3·0 
to −1·3)
−5·1% 
(−6·6 to 
−3·4)
 Lebanon 92·2 
(4·0 to 
403)
162 (8·5 
to 802)
254 
(13·1 to 
1090)
48·6 (0·8 to 
210)
63·9 
(2·1 to 
368)
113 
(3·3 to 
578)
−2·4% 
(−11·3 to 5 
4)
3·7% 
(−6·8 to 
117)
−0·6% 
(−10·4 to 
5·5)
−1·2% 
(−13·0 
to 8·4)
 Libya 95·0 
(4·8 to 
421)
93·9 
(5·1 to 
479)
189 
(10·9 to 
845)
47·3 (3·5 to 
201)
56·0 
(4·2 to 
261)
103 
(8·8 to 
436)
5·4% (−4·9 
to 14·2)
5·2% 
(−5·5 to 
13·1)
9·1% (0·9 to 
16·7)
3·2% 
(−5·7 to 
10·4)
 Morocco 557 (2 
8·7 to 
2580)
551 
(28·5 to 
2790)
1110 
(59·0 to 
4860)
246 (6·2 to 
1740)
356 (8·4 
to 2260)
602 
(16·0 
to 
3660)
5·8% (−4·3 
to 13·6)
−4·0% 
(−15·1 to 
3·9)
10·7% (−0·8 
to 17·5)
−4·6% 
(−19·4 
to 2·6)
 Oman 54·4 
(30·7to7
9·9)
541 
(241 to 
1040)
595 
(273 to 
1120)
11·4 (5·8 to 
19·2)
123 
(62·3 to 
181)
135 
(70·0 
to 199)
9·8% (7·1 
to 11·5)
4·3% 
(−2·1 to 
8·4)
9·9% (8·6 to 
11·1)
7·3% 
(0·1 to 
10·1)
 Palestine 9·2 (5·7 
to 14·5)
10·8 
(7·0 to 
16·3)
20·0 
(12·7 to 
30·8)
4·6 (3·8 to 
5·5)
5·7 (4·8 
to 6·7)
10·3 
(8·6to1
2· 1)
4·2% (2·5 
to 5·5)
2·3% 
(−0·3 to 
4·5)
9·9% (8·8 to 
11·4)
0·7% 
(−0·5 to 
1·9)
 Qatar 2·4 (1·8 
to 3·1)
8·1 (6·4 
to 10·5)
10·5 
(8·5 to 
13·3)
2·2 (1·5 to 
2·9)
4·7 (4·1 
to 5·7)
7·0 
(5·8 to 
8·1)
−8·0% 
(−9·6 to 
−6·5)
−2·4% 
(−3·9 to 
−0·7)
−2·4% (−3·8 
to −1·0)
−5·0% 
(−6·3 to 
−2 9)
 Saudi 
Arabia
331 
(187 to 
706)
342 
(198 to 
652)
673 
(397 to 
1270)
245 (191 to 
324)
281 
(209 to 
353)
526 
(402 to 
676)
1·0% (−3·6 
to 4·2)
−0·2% 
(−4·0 
to5·2)
6·4% (4·0 to 
8·5)
−1·4% 
(−4·5 to 
0·8)
 Sudan 3760 
(1610 to 
7140)
2810 
(1410 to 
5420)
6570 
(3440 to 
12200)
3110 (2130 
to 4230)
2190 
(1650 to 
3010)
5300 
(4150 
to 
6740)
3·7% (0·7 
to 8·7)
−5·7% 
(−11·3 to 
−0·3)
15·6% (12·3 
to 18·0)
0·3% 
(−1·4 to 
2 0)
 Syria 11·0 
(7·2 to 
16·8)
30·8 
(16·5 to 
52·2)
41·8 
(28·7 to 
62·9)
6·6 (4·8 to 
9·7)
4·7 (3·2 
to 8·1)
11·3 
(8·2 to 
17·7)
2·6% (−0·1 
to 4·2)
1·6% 
(−1·1 to 
5·7)
3·7% (2 2 to 
4·7)
−4·1% 
(−7·0 to 
−0·1)
 Tunisia 180 
(19·3 to 
750)
251 
(26·5 to 
905)
431 
(50·0 to 
1630)
80·4 (2 4 to 
392)
113 (2·8 
to 455)
194 
(5·4 to 
790)
9·8% (2·6 
to 17·1)
4·3% 
(−4·4 to 
11·1)
11·0% (2·9 
to 16·5)
5·9% 
(−8·0 to 
11·4)
 Turkey 171 
(114 to 
255)
303 
(203 to 
438)
474 
(325to6
89)
70·6 (55·8 
to 85·2)
130 
(102 to 
156)
200 
(159 to 
236)
12·3% (6·9 
to 50·5)
1·5% 
(−1·1 to 
3·5)
13·5% (9·0 
to 43·3)
6·5% 
(3·3 to 
9·1)
 United 
Arab 
Emirates
42·0 (2 
1 to 
191)
195 (8·7 
to 1210)
237 
(11·2 to 
1290)
23·5 (1·9 to 
98·8)
181 
(11·0 to 
967)
205 
(12·5 
to 
1020)
11·2% 
(−3·9 to 
22·2)
1·8% 
(−9·9 to 
12·3)
10·2% 
(1·3to18·2)
20·3% 
(−5·0 to 
34·3)
 Yemen 393 
(13·5 to 
1820)
689 
(25·9 to 
3110)
1080 
(43·2 to 
4940)
135 (1·9 to 
699)
252 (4·7 
to 1320)
387 
(7·3 to 
1940)
1·6% (−9·9 
to 13·9)
5·5% 
(−7·6 to 
13·7)
3·9% (−5·5 
to 16·3)
−0·0% 
(−22·1 
to 9·6)
South Asia 49 900 
(29 500 
to 82 
500)
67 700 
(39 100 
to 116 
000)
118 000 
(69 100 
to 195 
000)
26 200 (22 
500 to 35 
100)
34 500 
(28 300 
to 51 
000)
60 700 
(51 
400 to 
84 
900)
6·1% (1·1 
to 11·6)
−1·8% 
(−5·4 to 
2·1)
30·2% (23·9 
to 35·9)
−12·4
% 
(−14·0 
to −9·4)
Bangladesh
414 
(6·6to19
80)
542 
(15·9 to 
2330)
956 
(21·7to4
120)
266 (0·8 to 
1520)
361 (1·8 
to 1850)
627 (2 
4 to 
3170)
52·2% 
(31·4 to 
60·7)
−1·8% 
(−11·7 to 
8·9)
43·8% (19·6 
to 53·6)
8·8% 
(−11·1 
to 18·6)
 Bhutan 41·0 
(0·7 to 
186)
94·2 
(2·6to42
0)
135 (3·3 
to 597)
24·1 (0·1 to 
122)
57·2 
(1·2 to 
254)
81·3 
(1·4 to 
363)
3·9% 
(−10·9 to 
19·1)
1·6% 
(−8·1 to 
11·1)
8·9% (−2·9 
to 22·1)
4·9% 
(−7·7 to 
16·5)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 India 43600 
(27 600 
to 65 
800)
55800 
(34 600 
to 
82900)
99400 
(62 900 
to 
148000)
23400 
(21800 to 
25100)
28700 
(27100 
to 
30500)
52100 
(49 
200 to 
55400)
5·9% (1·1 
to 11·4)
−2·3% 
(−5·7 to 
1·8)
34·0% (30·3 
to 37·4)
−13·6% 
(−14·3t
o 
−12·9)
 Nepal 824 
(12·9 to 
3920)
1420 
(37·3 to 
6520)
2240 
(52·3 to 
9930)
762 (3·4 to 
4880)
1860 
(12·8 to 
9710)
2620 
(17·3 
to 
13500)
30·1% 
(16·4 to 
44·9)
−11·1% 
(−21·4 to 
−1·3)
65·3% (52·9 
to 81·6)
−2·2% 
(−19·4t
o6·0)
 Pakistan 4990 
(81·4 to 
21300)
9930 
(306 to 
42 500)
14900 
(445 to 
62 900)
1780 (7·5 to 
9830)
3530 
(23·1 to 
16500)
5310 
(31·3 
to 
25900)
6·3% (−7·3 
to 21·3)
7·8% 
(−1·7 to 
18·8)
4·4% (−7·9 
to 18·3)
12·9% 
(−11·2 
to 25·5)
Southeast 
Asia, east 
Asia, and 
Oceania
39 200 
(30 600 
to 50 
500)
92 200 
(69 600 
to 127 
000)
131 000 
(103 
000 to 
175 
000)
26 600 (22 
900 to 32 
800)
62 400 
(58 300 
to 68 
100)
89 000 
(81 
900 to 
99 
600)
1·8% (0·3 
to 3·8)
−3·2% 
(−4·9 to 
−1·5)
13·5% (12·6 
to 14·8)
−0·6% 
(−1·8 to 
0·5)
East Asia 7320 
(3270 to 
12800)
28000 
(11300 
to 
48800)
35300 
(14 500 
to 
61500)
9070 (8330 
to 10400)
27400 
(25400 
to 
30500)
36500 
(33 
800 to 
40900)
9·3% (5·8 
to 11·9)
−7·0% 
(−13·3to 
−4·6)
8·6% (7·3 to 
10·3)
4·7% 
(3·9 to 
5·3)
 China 6860 
(3020 to 
11400)
26500 
(10 900 
to 
45900)
33300 
(13 800 
to 
57300)
8640 (8080 
to 9140)
26200 
(24 500 
to 
27600)
34800 
(32 
600 to 
36 
600)
9·2% (5·5 
to 11·9)
−7·2% 
(−13·3 to 
−4·9)
8·5% (7·3 to 
10·2)
4·7% 
(3·9 to 
5·2)
 North 
Korea
321 (2 4 
to 1970)
869 
(6·6to52
70)
1190 
(9·4 to 
7690)
263 (3·1 to 
1460)
634 (9·2 
to 3590)
897 
(13·6 
to 
5260)
11·0% 
(−0·2 to 
27·3)
−1·6% 
(−16·8 to 
8·3)
14·5% (1·9 
to 40·9)
5·7% 
(−2·6 to 
15·8)
 Taiwan 
(province of 
China)
21·7 
(10·1 to 
35·8)
189 
(94·4 to 
340)
210 
(106 to 
378)
21·8 (19·8 
to 23·9)
176 
(161 to 
193)
198 
(182 to 
215)
8·8% 
(5·3to11·8)
−7·8% 
(−13·5 to 
−5·2)
7·0% (6·4 to 
7·5)
4·0% 
(3·0 to 
5·1)
Oceania 1980 
(247 to 
7710)
1550 
(214 to 
6120)
3530 
(461 to 
13 200)
778 (391 to 
2400)
729 
(342 to 
2050)
1510 
(747 to 
4310)
18·8% (9·9 
to 26·3)
−4·7% 
(−16·2 to 
2·1)
27·4% (21·1 
to 33·9)
−7·9% 
(−11·8 
to −3·6)
 American 
Samoa
0·2 (0·1 
to 0·4)
0·5 (0·3 
to 0·8)
0·7 (0 4 
to 1·1)
0·1 (0·1 to 
0·1)
0·2 (0·2 
to 0·3)
0·3 
(0·3 to 
0·4)
−1·8% 
(−8·6to4·5)
3·2% (−0 
4 to 7·2)
7·0% (2 1 to 
15·3)
0·6% 
(−1·8 to 
2·8)
 Federated 
States of 
Micronesia
34·5 
(0·2 to 
235)
39·6 (0 
4 to 
246)
74·1 
(0·6 to 
434)
12·2 (0·1 to 
51·6)
18·3 
(0·3 to 
83·6)
30·4 
(0·5 to 
131)
10·2% 
(−3·0 to 
26·1)
7·3% 
(−7·3 to 
18·0)
9·5% (−1·5 
to 27·8)
12·7% 
(2·5 to 
25·8)
 Fiji 24·8 
(18·1 to 
34·7)
22 1 
(16·2 to 
30·7)
46·9 
(35·9 to 
64·6)
5·5 (3·5 to 
9·6)
4·9 (3·0 
to 8·3)
10·4 
(7·0 to 
18·1)
2·5% (−3·9 
to 7·4)
4·3% (2·8 
to 6·0)
8·9% (5·8 to 
14·1)
−3·2% 
(−6·1 to 
1·4)
 Guam 0·8 (0·4 
to 1·4)
6·7 (3·8 
to 11·3)
7·5 (4·2 
to 12·6)
0·6 (0·4 to 
0·8)
3·7 (2·9 
to 4·7)
4·3 
(3·3 to 
5·5)
−3·6% 
(−10·8 to 
2·9)
4·0% (0·4 
to 7·8)
5·0% (−0 0 
to 13·9)
0·6% 
(−1·9 to 
2·5)
 Kiribati 0·3 (0·2 
to 0·7)
0·4 (0·2 
to 0·6)
0·7 (0·4 
to 1·3)
0·2 (0·2 to 
0·3)
0·3 (0·2 
to 0·3)
0·5 
(0·4 to 
0·6)
−6·6% 
(−8·0 to 
−5·0)
0·9% 
(−3·5 to 
6·5)
1·3% (−1·3 
to 4·1)
−3·5% 
(−4·3 to 
−2·6)
 Marshall 
Islands
3·9 (0·0 
to 24·5)
3·8 (0·0 
to 26·8)
7·7 (0·1 
to 50 4)
1·4 (0·0 to 
7·9)
1·3 (0·0 
to 8·2)
2·7 
(0·0 to 
15·8)
0·1% 
(−11·7 to 
15·0)
7·9% 
(−5·4 to 
16·2)
5·8% (−4·2 
to 20·9)
4·2% 
(−7·5 to 
16·3)
 Northern 
Mariana 
Islands
0·2 (0·1 
to 0·3)
0·6 (0·3 
to 0·9)
0·7 (0·4 
to 1·2)
0·1 (0·1 to 
0·2)
0·3 (0·2 
to 0·4)
0·4 
(0·3 to 
0·5)
−0·0% 
(−6·6to5·8)
3·9% (0·5 
to 7·5)
8·5% (4·0 to 
16·3)
1·0% 
(−1·2 to 
3·3)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Papua New 
Guinea
1730 
(155 to 
7240)
1320 
(108 to 
5660)
3050 
(268 to 
12 000)
688 (339 to 
2200)
636 
(285 to 
1880)
1320 
(627 to 
4030)
25·2% 
(19·0 to 
34·9)
−5·9% 
(−19·4 to 
1·3)
48·6% (40·7 
to 65·2)
−9·1% 
(−13·0 
to −4 4)
 Samoa 13·2 
(0·1 to 
85·8)
13·2 
(0·1 to 
95·2)
26·4 
(0·3 to 
172)
4·6 (0·1 to 
25·7)
4·5 (0·1 
to 26·8)
9·1 
(0·1 to 
55·5)
0·7% 
(−11·3 to 
15·9)
8·1% 
(−5·0 to 
16·3)
6·1% (−4·2 
to 21·4)
4·6% 
(−6·7 to 
17·0)
 Solomon 
Islands
42·8 (0 
4 to 
278)
37·0 (0 
4 to 
268)
79·8 
(0·9 to 
519)
15·1 (0·2 to 
91·6)
13·0 
(0·2 to 
77·9)
28·1 (0 
4 to 
166)
−0·1% 
(−12·2 to 
14·5)
7·5% 
(−5·3 to 
15·8)
5·9% (−4·0 
to 20·8)
3·7% 
(−7·5 to 
15·9)
 Tonga 1·1 (0·6 
to 2·0)
1·5 (0·8 
to 2·5)
2·6 (1·4 
to 4·4)
0·5 
(0·4to0·6)
0·7 (0·6 
to 0·9)
1·2 
(0·9 to 
1·6)
−0·2% 
(−7·0 to 
5·8)
4·0% (0·5 
to 8·1)
8·4% (3·7 to 
16·3)
1·5% 
(−1·0 to 
3·4)
 Vanuatu 20·7 
(0·2 to 
137)
17·7 
(0·2 to 
123)
38·3 (0 
4 to 
254)
7·0 (0·1 to 
39·1)
6·4 (0·1 
to 36·7)
13·4 
(0·2 to 
78·5)
3·3% (−9·0 
to 18·4)
2·4% 
(−19·4 to 
15·7)
6·8% (−3·5 
to 22·4)
4·0% 
(−5·8 to 
16·0)
Southeast 
Asia
29 800 
(24 100 
to 38 
400)
62 700 
(52 500 
to 81 
000)
92 500 
(78 300 
to 116 
000)
16 800 (13 
300 to 22 
800)
34 300 
(30 700 
to 38 
900)
51 000 
(44 
700 to 
60 
300)
−1·5% 
(−4·2 to 
1·6)
−2·2% 
(−3·8 to 
0·5)
16·4% (15·0 
to 18·0)
−3·4% 
(−5·5 to 
−1·7)
 Cambodia 561 
(108 to 
1390)
485 
(94·4 to 
1230)
1050 
(208 to 
2520)
502 (303 to 
893)
876 
(546 to 
1380)
1380 
(884 to 
1990)
2·3% (−3·8 
to 9·6)
−10 4% 
(−23·8 to 
−2·7)
36·8% (32 1 
to 42·2)
−15·2% 
(−18·6 
to 
−11·4)
 Indonesia 6480 
(5090 to 
8730)
11 300 
(8800 to 
15 600)
17 700 
(14 100 
to 24 
100)
2500 (2190 
to 3060)
4270 
(3850 to 
4870)
6770 
(6090 
to 
7680)
5·8% (3·1 
to 64·4)
3·2% (1·8 
to 4·8)
32·1% (30·8 
to 34·4)
6·9% 
(6·3 to 
7·6)
 Laos 223 (1·6 
to 1370)
579 (6·0 
to 3920)
802 (8·0 
to 5270)
138 (0·3 to 
1120)
388 (1·2 
to 2780)
526 
(1·5 to 
4300)
25·4% 
(14·4 to 
38·9)
−6·6% 
(−17·3 to 
1·9)
56·2% (40·6 
to 67·6)
1·6% 
(−14·3 
to 10·0)
 Malaysia 1200 
(904 to 
1540)
3180 
(2060 to 
3920)
4370 
(3010 to 
5230)
615 (328 to 
844)
964 
(744 to 
1270)
1580 
(1120 
to 
2070)
−0·7% 
(−3·5 to 
2·3)
0·2% 
(−2·1 to 
1·4)
19·4% (16·7 
to 22·2)
−3·2% 
(−6·7 to 
−1·1)
 Maldives 0·9 (0·7 
to 1·3)
0·3 (0·2 
to 0·4)
1·2 (0·9 
to 1·7)
0·6 (0·6 to 
0·7)
0·1 (0·1 
to 0·1)
0·8 
(0·7 to 
0·8)
4·2% (1·8 
to 6·9)
−2·3% 
(−4·9 to 
0·3)
6·5% (4·8 to 
8·4)
0·5% 
(−2·2 to 
3·3)
 Mauritius 104 
(71·7 to 
140)
194 
(145 to 
269)
298 
(233 to 
382)
16·4 (15·3 
to 17·5)
79·4 
(73·9 to 
85·3)
95·8 
(90·2 
to 102)
20·9% 
(18·9 to 
21·8)
3·1% (0·3 
to 5·8)
6·5% (6·0 to 
7·0)
5·3% 
(4·4 to 
6·2)
 Myanmar 4970 
(2730 to 
7240)
4740 
(2970 to 
7960)
9710 
(7320 to 
13 300)
2860 (1640 
to 4270)
2490 
(2010 to 
3690)
5350 
(4330 
to 
6700)
4·6% (3·0 
to 6·0)
−7·3% 
(−8·4 to 
−6·2)
34·7% (31·7 
to 37·7)
−12·6% 
(−14·4 
to 
−10·4)
 Philippines 3170 
(1880 to 
5090)
11 100 
(6600 to 
18 300)
14 300 
(8480 to 
23 200)
1390 (1330 
to 1460)
2790 
(2650 to 
2930)
4180 
(4030 
to 
4340)
0·0% (−8·4 
to 9·3)
5·1% (1·6 
to 8·6)
6·5% (6·3 to 
6·7)
−3·1% 
(−3·5 to 
−2·7)
 Sri Lanka 101 
(63·8 to 
153)
190 
(103 to 
289)
291 
(171 to 
432)
25·2 (17·0 
to 35·6)
30·6 
(19·9 to 
46·5)
55·8 
(37·4 
to 
81·6)
−0·6% 
(−9·6 to 
10·8)
7·8% (2·3 
to 11·9)
4·3% (1·8 to 
8·8)
−4·1% 
(−8 4 to 
−0 0)
 Seychelles 2·4 (1·9 
to 3·3)
3·4 (2·6 
to 4·8)
5·8 (4·5 
to 8·1)
2·4 (2 2 to 
2·7)
3·4 (3·1 
to 3·9)
5·8 
(5·3 to 
6·5)
−5·1% 
(−6·3 to 
−3·7)
−1·4% 
(−3·3 to 
0·3)
12·5% (9·1 
to 15·3)
−0·3% 
(−1·0 to 
0·4)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Thailand 9550 
(6490 to 
15 600)
15 000 
(12 300 
to 20 
900)
24 500 
(19 300 
to 34 
300)
7660 (4790 
to 13 900)
11 700 
(9750 to 
14 500)
19 400 
(14 
900 to 
27 
600)
−5·3% 
(−10·1 to 
−1·4)
−3·6% 
(−6·0 to 
2·2)
14·6% (12·1 
to 18·1)
−1·5% 
(−6·4 to 
2·3)
 Timor-
Leste
97·3 
(0·9 to 
580)
153 (1·8 
to 1000)
250 (2·8 
to 1540)
90·9 (1·0 to 
500)
132 (2·5 
to 756)
223 
(3·8 to 
1280)
−8·1% 
(−19·3 to 
5·1)
−4·4% 
(−14·7 to 
3·7)
15·1% (7·5 
to 26·8)
−1·9% 
(−11·0 
to 7·6)
 Vietnam 3360 
(2330 to 
6080)
15 700 
(12 700 
to 21 
000)
19 100 
(15 200 
to 25 
900)
933 (458 to 
2630)
10 500 
(8570 to 
13 100)
11 400 
(9060 
to 15 
200)
5·8% (3·9 
to 8·1)
−2·3% 
(−3·8 to 
−0·5)
16·7% (14·6 
to 18·5)
−1·3% 
(−3·0 to 
1·1)
Sub-
Saharan 
Africa
723 000 
(558 
000 to 
927 
000)
487 000 
(371 
000 to 
621 
000)
1210 
000 
(929 
000 to 
1540 
000)
362 000 
(333 000 to 
392 000)
349 000 
(327 
000 to 
375 
000)
712 
000 
(669 
000 to 
759 
000)
−2·8% 
(−3·8 to 
−1·9)
−5·9% 
(−8·2 to 
−3·6)
7·8% (7·0 
to 8·7)
−11·1
% 
(−11·5 
to 
−10·6)
Central sub-
Saharan 
Africa
32 100 
(17 800 
to 52 
300)
17 200 
(10 100 
to 27 
500)
49 300 
(27 900 
to 80 
100)
27 700 (24 
200 to 31 
800)
16 600 
(14 600 
to 18 
700)
44 300 
(39 
000 to 
50 
400)
−2·9% 
(−4·6 to 
−1·3)
−7·1% 
(−12·3to 
−2·9)
3·4% (2·1 to 
4·7)
−9·1% 
(−10·2 
to −7·8)
 Angola 12 600 
(4910 to 
22 200)
6380 
(2680 to 
11 300)
19 000 
(7540 to 
32 800)
9750 (7300 
to 12 700)
4840 
(3670 to 
6290)
14 600 
(11 
100 to 
18 
900)
12·4% (6·2 
to 20·4)
−6·3% 
(−16·5 to 
0·6)
21·7% (17·2 
to 24·7)
0·3% 
(−1·0 to 
1·7)
 Central 
African 
Republic
3470 
(705 to 
7620)
1520 
(325 to 
3400)
4990 
(1070 to 
11 000)
3050 (2480 
to 3810)
2270 
(1880 to 
2770)
5320 
(4490 
to 
6520)
−7·8% 
(−11·0 to 
−5·5)
−3·1% 
(−18·5 to 
4·5)
5·4% (3·4 to 
7·9)
−10·4% 
(−11·9 
to −8·9)
 Congo 
(Brazzaville)
4390 
(3070 to 
5940)
2570 
(1820 to 
3450)
6970 
(4980 to 
9250)
3310 (2570 
to 4140)
2260 
(1850 to 
2780)
5570 
(4460 
to 
6850)
−4·5% 
(−6·6 to 
−1·7)
−2·2% 
(−4·3 to 
−0 4)
0·9% (−1·1 
to 2·9)
−4·4% 
(−5·7 to 
−3·4)
Democratic 
Republic of 
the Congo
9590 
(1920 to 
21 200)
5630 
(1590 to 
12 000)
15 200 
(3500 to 
33 400)
10 100 
(7970 to 12 
900)
6300 
(5080 to 
7870)
16 400 
(13 
200 to 
20 
600)
−5·3% 
(−7·5 to 
−2·8)
−10·3% 
(−2 6·0 to 
−2 9)
2·0% (0·6 to 
3·6)
−14·0% 
(−15·7 
to 
−11·6)
 Equatorial 
Guinea
1510 
(381 to 
3510)
853 
(248 to 
2010)
2360 
(618 to 
5390)
1090 (808 
to 1500)
665 
(481 to 
921)
1750 
(1320 
to 
2380)
8·2% (2 5 
to 15·5)
−8·3% 
(−22·7 to 
−0·3)
17·5% (11·9 
to 21·1)
−0·8% 
(−3·5 to 
1·9)
 Gabon 497 
(277 to 
872)
228 
(128 to 
411)
725 
(404 to 
1300)
410 (282 to 
641)
234 
(162 to 
355)
644 
(465 to 
963)
0·3% (−4·0 
to 3·7)
−12·8% 
(−16·9 to 
−7·1)
11·4% (9·4 
to 13·5)
−17·2% 
(−20 4 
to 
−14·0)
Eastern sub-
Saharan 
Africa
259 000 
(187 
000 to 
361 
000)
175 000 
(128 
000 to 
243 
000)
434 000 
(314 
000 to 
603 
000)
121 000 
(111 000 to 
134 000)
122 000 
(113 
000 to 
132 
000)
242 
000 
(226 
000 to 
263 
000)
−5·8% 
(−6·9 to 
−4·9)
−6·2% 
(−9·3 to 
−2 5)
5·1% (4·1 to 
6·3)
−13·9% 
(−14 4 
to 
−13·2)
 Burundi 1880 
(410 to 
4450)
1160 
(271 to 
2610)
3040 
(683 to 
7270)
1160 (859 
to 1600)
1460 
(1210 to 
1800)
2620 
(2150 
to 
3300)
−17·8% 
(−24·1 to 
−10·7)
2·8% 
(−11·6 to 
11·2)
10·5% (5·8 
to 14·1)
−19·9% 
(−22·1 
to 
−16·8)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Comoros 3·3 (0·1 
to 17·7)
10·2 
(0·2 to 
58·5)
13·4 
(0·3 to 
72·3)
0·3 (0·0 to 
3·1)
1·3 (0·0 
to 10·0)
1·6 
(0·0 to 
11·9)
10·4% 
(−4·6 to 
35·2)
12·8% 
(0·7 to 
23·5)
15·2% (2·6 
to 41·0)
2·7% 
(−17·5 
to 12·5)
 Djibouti 474 
(132 to 
1030)
345 
(99·6 to 
744)
820 
(237 to 
1720)
415 (298 to 
588)
308 
(222 to 
432)
724 
(535 to 
987)
14·9% (3·8 
to 26·9)
−1·5% 
(−12 7 to 
5·0)
44·0% (32·6 
to 59·1)
−6·5% 
(−8·7 to 
−4·3)
 Eritrea 1070 
(267 to 
2190)
695 
(202 to 
1380)
1770 
(479 to 
3570)
944 (724 to 
1220)
577 
(448 to 
748)
1520 
(1190 
to 
1950)
−8·5% 
(−14·8 to 
−2·3)
1·6% 
(−10·6 to 
9 4)
15·2% (11·4 
to 18·0)
−11·7% 
(−13·5 
to −9·8)
 Ethiopia 9080 
(4950 to 
14 600)
5400 
(3190 to 
8540)
14 500 
(8280 to 
23 000)
9180 (7760 
to 10 800)
8000 
(6850 to 
9360)
17 200 
(14 
600 to 
20 
100)
−18·9% 
(−21·5 to 
−16·3)
−1·3% 
(−7·6 to 
4·1)
7·4% (4·6 to 
9·6)
−19·7% 
(−20·9 
to 
−18·4)
 Kenya 55 900 
(38 000 
to 81 
100)
36 900 
(24 300 
to 57 
800)
92 800 
(64 000 
to 136 
000)
24 700 (22 
400 to 27 
800)
23 800 
(21 800 
to 26 
500)
48 500 
(44 
600 to 
54 
000)
−6·1% 
(−7·5 to 
−4·8)
−3·5% 
(−6·3 to 
−0·5)
10·1% (9·0 
to 11·1)
−11·0% 
(−11·7 
to 
−10·1)
Madagascar
5230 
(585 to 
24 800)
3570 
(438 to 
17 500)
8800 
(1020 to 
42 100)
1450 (1090 
to 2180)
1080 
(822 to 
1680)
2530 
(1920 
to 
3820)
18·4% (8·0 
to 31·5)
9·8% 
(−10·5 to 
24·4)
46·0% (36·8 
to 64·4)
−3·6% 
(−6·5 to 
−0·5)
 Malawi 16 600 
(7920 to 
26 500)
12 000 
(6410 to 
18 600)
28 600 
(14 300 
to 45 
200)
10 700 
(8750 to 13 
300)
11 200 
(9620 to 
13 200)
21 900 
(18 
900 to 
25 
900)
−7·0% 
(−8·5 to 
−5·5)
−10·8% 
(−18·9 to 
−5·3)
8·5% (6·0 to 
114)
−17·2% 
(−18·5 
to 
−14·9)
Mozambique
79 100 
(51 900 
to 117 
000)
54 000 
(35 400 
to 76 
500)
133 000 
(88 800 
to 192 
000)
31700 (24 
300 to 42 
000)
30 400 
(25 400 
to 38 
200)
62 100 
(50 
600 to 
78 
100)
5·4% (3·5 
to 7·5)
−5·2% 
(−9·5 to 
−1·7)
18·4% (16·0 
to 20·6)
−8·0% 
(−9·2 to 
−6·7)
 Rwanda 3930 
(2540 to 
5920)
2390 
(1490 to 
3730)
6320 
(4030 to 
9450)
1660 (1320 
to 2120)
1300 
(1070 to 
1690)
2960 
(2460 
to 
3710)
−6·1% 
(−9·3 to 
−2·1)
−7·2% 
(−11·7 to 
−2·5)
10·2% (6·4 
to 12·9)
−17·0% 
(−18·1 
to 
−15·3)
 Somalia 1320 
(55·4 to 
5050)
1060 
(50·4 to 
4390)
2380 
(106 to 
9370)
1280 (465 
to 4060)
1110 
(402 to 
3280)
2390 
(867 to 
7270)
−1·4% 
(−10·6 to 
7·8)
−5·8% 
(−23·7 to 
1·7)
15·6% (8·7 
to 21·7)
−7·0% 
(−9·8 to 
−4·6)
 South 
Sudan
2590 
(105 to 
9770)
1610 
(60·5 to 
5990)
4200 
(162 to 
15 700)
2070 (766 
to 6590)
1640 
(536 to 
5250)
3710 
(1320 
to 11 
600)
0·2% (−5·4 
to 9·5)
−5·7% 
(−15·6 to 
−2·9)
13·0% (8·9 
to 18·2)
−6·6% 
(−10·2 
to −3·5)
 Tanzania 31 000 
(1470 to 
97 700)
19 400 
(1350 to 
61 800)
50 500 
(2820 to 
159 
000)
12 600 
(9670 to 16 
800)
15 700 
(12 200 
to 20 
000)
28 300 
(22 
700 to 
35 
200)
−8·3% 
(−10·8 to 
−6·0)
−6·6% 
(−41·9 to 
7·7)
4·8% (3·1 to 
6·6)
−17·7% 
(−19·5 
to 
−15·3)
 Uganda 24 100 
(3410 to 
84 500)
16 200 
(3020 to 
52 600)
40 300 
(6330 to 
133 
000)
12 300 (10 
000 to 14 
900)
13 600 
(11 600 
to 16 
500)
25 900 
(22 
300 to 
30 
500)
−3·8% 
(−7·7 to 
0·2)
−11·4% 
(−35·9 to 
2·5)
−3·4% (−5·0 
to −1·2)
−15·7% 
(−16·9 
to 
−13·8)
 Zambia 26 600 
(17 800 
to 38 
700)
20 200 
(13 400 
to 29 
200)
46 800 
(31 600 
to 67 
500)
10 300 
(8110 to 13 
000)
11 500 
(9670 to 
14 200)
21 800 
(18 
500 to 
−5·4% 
(−6·7 to 
−4·2)
−8·3% 
(−12·2 to 
−4·2)
5·8% (3·4 to 
8·5)
−15·5% 
(−16·7 
to 
−13·7)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
26 
000)
Southern sub-
Saharan 
Africa
213 000 
(157 
000 to 
281000)
153 000 
(110 
000 to 
201 
000)
366 000 
(269 
000 to 
470 
000)
81 100 (70 
600 to 93 
700)
87 300 
(77 700 
to 98 
900)
168 
000 
(152 
000 to 
189 
000)
2·4% (0·6 
to 3·9)
−5·6% 
(−8·5 to 
−3·0)
15·0% (12·3 
to 17·5)
−12·1% 
(−13·1 
to 
−11·1)
 Botswana 5230 
(3610 to 
7200)
3860 
(2580 to 
5530)
9100 
(6370 to 
12 400)
1650 (1230 
to 2460)
2450 
(1620 to 
3760)
4100 
(3180 
to 
5550)
−3·1% 
(−4·5 to 
−1·8)
−5·3% 
(−9·1 to 
−1·7)
9·2% (6·7 to 
12·2)
−14·7% 
(−17·2 
to 
−12·1)
 eSwatini 1360 
(324 to 
2570)
1000 
(292 to 
1850)
2360 
(620 to 
4360)
1240 (1030 
to 1460)
1270 
(1060 to 
1550)
2510 
(2200 
to 
2850)
14·2% (8·5 
to 19·5)
−21·8% 
(−36·1 to 
−15·1)
35·5% (30·6 
to 38·5)
−15·4% 
(−17·3 
to 
−12·5)
 Lesotho 7280 
(5080 to 
9660)
5390 
(3740 to 
7310)
12 700 
(9140 to 
16 700)
3220 (2620 
to 4060)
3110 
(2510 to 
4050)
6330 
(5330 
to 
7830)
2·8% (1·1 
to 4·5)
−7·1% 
(−10·7 to 
−4·4)
17·9% (15·6 
to 20·5)
−10·9% 
(−11·9 
to −9·2)
 Namibia 5450 
(3180 to 
8970)
3950 
(2320 to 
6350)
9400 
(5550 to 
15100)
2090 (1390 
to 3130)
1870 
(1400 to 
2540)
3960 
(3020 
to 
5290)
2·4% (0·8 
to 5·1)
−5·8% 
(−10·8 to 
−1·2)
13·2% (8·9 
to 16·4)
−12·4% 
(−14·6 
to 
−10·1)
 South 
Africa
160 000 
(120 
000 to 
205 
000)
116 000 
(85 900 
to 151 
000)
276 000 
(211 
000 to 
346 
000)
64 600 (54 
900 to 77 
300)
70 800 
(61 300 
to 82 
200)
135 
000 
(119 
000 to 
156 
000)
12·8% 
(11·3 to 
14·2)
−5·7% 
(−7·9 to 
−3·8)
34·0% (32·5 
to 35·3)
−10·5% 
(−11·6 
to −9·4)
 Zimbabwe 33 900 
(1130 to 
76 700)
22 300 
(1100 to 
51 200)
56 300 
(2210 to 
124 
000)
8300 (6710 
to 10 300)
7760 
(6530 to 
9630)
16 100 
(13 
900 to 
18 
900)
−8·5% 
(−11·0 to 
−6·3)
−3·0% 
(−40·1 to 
7·9)
7·5% (5·0 to 
10·0)
−20·8% 
(−22·9 
to 
−17·4)
Western sub-
Saharan 
Africa
218 000 
(152 
000 to 
290 
000)
142 000 
(99 500 
to 190 
000)
360 000 
(258 
000 to 
470 
000)
133 000 
(111 000 to 
160 000)
124 000 
(106 
000 to 
145 
000)
257 
000 
(223 
000 to 
294 
000)
−1·6% 
(−3·1 to 
−0·2)
−4·9% 
(−7·4 to 
−2·5)
10·2% (8·0 
to 11·8)
−6·7% 
(−7·3 to 
−6·1)
 Benin 2090 
(1140 to 
3250)
1320 
(743 to 
2090)
3420 
(1870 to 
5220)
1090 (801 
to 1500)
719 
(550 to 
951)
1810 
(1380 
to 
2390)
4·2% (0·5 
to 13·5)
−5·0% 
(−10·2 to 
−0·6)
24·8% (21·8 
to 27·2)
−13·2% 
(−15·0 
to 
−11·3)
 Burkina 
Faso
1890 
(404 to 
3830)
1240 
(314 to 
2530)
3140 
(725 to 
6210)
1060 (775 
to 1460)
1580 
(1240 to 
2010)
2640 
(2080 
to 
3380)
−15·1% 
(−17·7to 
−12·9)
−6·8% 
(−25·2 to 
1·7)
−1·3% (−3·2 
to 1·2)
−16·9% 
(−18·4 
to 
−15·0)
 Cameroon 18 800 
(5450 to 
30 900)
10 400 
(3390 to 
17 400)
29 100 
(8970 to 
47 100)
12 300 
(9480 to 16 
200)
10 500 
(8550 to 
13 400)
22 800 
(18 
600 to 
28 
800)
3·6% (1·8 
to 5·3)
−6·7% 
(−18·4 to 
−2·1)
14·0% (12·2 
to 15·6)
−7·9% 
(−9·5 to 
−6·4)
 Cape 
Verde
170 
(114 to 
239)
155 
(103 to 
227)
324 
(229 to 
459)
57·2 (30·8 
to 95·5)
67·6 
(47·5 to 
98·3)
125 
(83·5 
to 187)
−3·1% (−5 
0 to −1·2)
−0·1% 
(−1·8 to 
1·5)
8·2% (6·5 to 
9·8)
−6·5% 
(−8·9 to 
−4·3)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
 Chad 5040 
(1940 to 
8830)
3520 
(1330 to 
5960)
8560 
(3260 to 
14700)
2500 (1710 
to 3620)
2430 
(1830 to 
3270)
4930 
(3660 
to 
6780)
−5·4% 
(−8·7 to 
−2·1)
−4·5% 
(−15·0 to 
0·7)
9·3% (5·4 to 
12 5)
−10·6% 
(−12·2 
to −9·0)
Côted’Ivoire
27 300 
(4380 to 
48 500)
18 000 
(3000 to 
31 800)
45 200 
(7400 to 
80 300)
8520 (5650 
to 11 900)
10 300 
(8000 to 
13 400)
18 800 
(13 
700 to 
25 
000)
−7·6% 
(−11·0 to 
0·6)
−0·4% 
(−17·4 to 
7·5)
2·3% (−2 1 
to 6·1)
−9·3% 
(−11·4 
to −7·0)
 The 
Gambia
718 
(225 to 
1300)
492 
(153 to 
899)
1210 
(375 to 
2150)
424 (2 85 to 
633)
458 
(342 to 
632)
883 
(644 to 
1220)
9·2% (6·5 
to 12 3)
−8·3% 
(−19·6 to 
−3·3)
21·0% (18·4 
to 23·3)
−4·3% 
(−6·2 to 
−2·5)
 Ghana 15 900 
(8840 to 
26 000)
7210 
(3910 to 
12 300)
23 100 
(12 700 
to 37 
900)
8190 (6480 
to 10 600)
5690 
(4540 to 
7190)
13 900 
(11 
200 to 
17 
500)
−4·4% 
(−6·0 to 
−2·8)
−3·0% 
(−8·5 to 
1·6)
6·7% (3·5 to 
9·6)
−8·2% 
(−9·3 to 
−7·2)
Guin
ea
3720 (2010 to6010) 1
9
8
0 
(
1
1
0
0 
t
o 
3
1
8
0
)
5700 
(3150 
to 
9090)
1750 (1280 to 
2400)
1240 
(950 to 
1620)
2
9
9
0 
(
2
2
8
0 
to 
3
9
2
0
)
4·3% (1·5 to 
7·5)
−8·2% (−13·8 to 
−4·5)
13·2
% 
(10·
2 to 
15·6
)
−
8·
7
% 
(−
1
0·
5 
to 
−
6·
9)
Guin
ea-
Biss
au
1460 (516 to 2760) 8
7
5 
(
3
1
4 
t
o 
1
6
7
0
)
2330 
(847 
to 
4320)
771 (536 to 1140) 669 
(478 to 
949)
1
4
4
0 
(
1
0
4
0 
to 
2
0
4
0
)
8·3% (6·5 to 10 
4)
−7·8% (−17·0 to 
−2 7)
14·4
% 
(12·
7 to 
16·1
)
−
5·
0
% 
(−
7·
0 
to 
−
2·
8)
Libe
ria
1410 (592 to 2500) 9
5
0 
(
3
9
3 
t
o 
1
7
4
0
)
2360 
(1030 
to 
4090)
892 (682 to 1180) 948 
(780 to 
1170)
1
8
4
0 
(
1
5
0
0 
to 
2
3
1
0
)
−7·8% (−17·1 to 
4·7)
2·2% (−5·5 to 
10·7)
14·5
% 
(7·7 
to 
19·8
)
−
8·
9
% 
(−
1
1·
3 
to 
−
6·
3)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
Mali
4610 (3100 to 6430) 3
1
7
0 
(
2
1
3
0 
t
o 
4
3
9
0
)
7780 
(5300 
to 10 
500)
3100 (2260 to 
4070)
2710 
(2180 to 
3390)
5
8
1
0 
(
4
5
8
0 
to 
7
3
5
0
)
−0·3% (−6·7 to 
6·0)
−4·9% (−7·2 to 
−2 9)
13·1
% 
(8·5 
to 
16·3
)
−
5·
3
% 
(−
6·
9 
to 
−
4·
1)
Mau
ritani
a
17·4 (0·4 to 101) 5
1
·
9 
(
1
·
1 
t
o 
3
1
1
)
69·3 
(1·8 to 
377)
3·3 (0·1 to 13·5) 16·3 
(0·2 to 
161)
1
9·
6 
(
0·
4 
to 
1
7
9
)
−5·1% (−20·1 to 
13·7)
−1·8% (−11·4 to 
6·9)
−5·8
% 
(−1
8·2 
to 
8·6)
−
5·
0
% 
(−
2
0·
5 
to 
3·
9)
Nige
r
1140 (606 to 1810) 8
0
8 
(
4
3
4 
t
o 
1
3
4
0
)
1950 
(1080 
to 
3020)
910 (683 to 1170) 1040 
(867 to 
1300)
1
9
5
0 
(
1
6
5
0 
to 
2
3
6
0
)
−4·8% (−8·7 to 
−1·7)
−4·5% (−9·3 to 
0·2)
16·1
% 
(14·
1 to 
17·6
)
−
1
2·
6
% 
(−
1
4·
2 
to 
−
1
0·
6)
Nige
ria
128 000 (88 000 to 
172 000)
8
8 
8
0
0 
(
6
1 
8
0
0 
t
o 
1
2
1 
0
0
0
)
217 
000 
(157 
000 to 
284 
000)
87 500 (67 200 to 
111 000)
81 600 
(64 000 
to 102 
000)
1
6
9 
0
0
0 
(
1
3
7 
0
0
0 
to 
2
0
6 
0
0
0
)
0·3% (−1·5 to 
1·9)
−5·1% (−7·4 to 
−2·7)
15·3
% 
(13·
1 to 
17·9
)
−
5·
2
% 
(−
6·
0 
to 
−
4·
5)
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New HIV infections, 2017 HIV deaths, 2017 Annualised rate of 
change in new 
infections
Annualised rate of 
change in HIV deaths
Females Males Total Females Males Total 1990–2007 2007–17 1990–2007 2007–
17
São 
Tom
é 
and 
Princ
ipe
0·4 (0·1 to 0·9) 1
·
2 
(
0
·
2 
t
o 
2
·
7
)
1·5 
(0·4 to 
3·5)
0·0 (0·0 to 0·1) 0·2 (0·1 
to 0·3)
0·
2 
(
0·
1 
to 
0 
4
)
−5·2% (−16·5 to 
4·7)
−0·5% (−10·6 to 
7·7)
0·5
% 
(−5·
2 to 
8·0)
−
1
0·
8
% 
(−
1
5·
5 
to 
−
5·
5)
Sene
gal
1830 (1090 to 2770) 1
0
4
0 
(
6
2
3 
t
o 
1
5
6
0
)
2870 
(1740 
to 
4320)
983 (721 to 1330) 821 
(655 to 
1060)
1
8
0
0 
(
1
4
1
0 
to 
2
3
5
0
)
0·4% (−1·8 to 2 
4)
−5·3% (−8·8 to 
−2·3)
14·2
% 
(12·
1 to 
16·0
)
−
9·
1
% 
(−
1
0·
9 
to 
−
7·
6)
Sierr
a 
Leon
e
1800 (222 to 4070) 1
1
6
0 
(
1
3
4 
t
o 
2
7
1
0
)
2960 
(371 
to 
6670)
1140 (807 to 
1580)
1050 
(818 to 
1400)
2
1
9
0 
(
1
7
2
0 
to 
2
8
5
0
)
18·5% (8·6 to 
35·2)
−11·4% (−34·2 to 
−4·0)
28·6
% 
(22·
0 to 
32 
1)
−
5·
3
% 
(−
8·
2 
to 
−
2 
4)
Togo
2430 (423 to 5400) 1
2
6
0 
(
2
7
2 
t
o 
2
6
3
0
)
3680 
(695 
to 
7790)
1920 (1460 to 
2590)
1950 
(1530 to 
2450)
3
8
7
0 
(
3
1
1
0 
to 
4
9
6
0
)
−1·0% (−3·6 to 
1·4)
−10·2% (−27·8 to 
−2 4)
16·4
% 
(13·
9 to 
18·8
)
−
1
3·
0
% 
(−
1
4·
7 
to 
−
1
1·
0)
Data are n (95% UI) or % (95% UI). SDI=socio-demographic index. UI=uncertainty interval. GBD=Global Burden of Diseases, Injuries, and Risk 
Factors study.
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